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Abstract
Acting at the N-methyl-D-aspartate (NMDA) excitatory amino
acid receptor, a variety of endogenously synthesized excitotoxic
compounds, including glutamate and quinolinic acid (QUIN), may play
a role in the pathogenesis of a number of neurodegenerative
diseases, including Huntington's Disease. When injected into the
corpus striatum of animals, QUIN produces a neurochemical pattern
of neuronal degeneration strikingly similar to that seen in the
striatum of a Huntington's Disease victim.
The goal of this Ph.D. thesis is to identify mechanisms of
neuronal degeneration in the striatum induced by excitotoxins using
both an in vitro tissue culture system and in vivo systemic
manipulations. In primary striatal cultures derived from neonatal
rats, examination of the mechanisms of excitotoxicity focused on
studies determining the relationships among activation of excitatory
amino acid receptors (especially the NMDA receptor), subsequent ion
fluxes into the cell, modulation of toxicity by outside factors and
second messenger systems, and the induction of cell death. In
addition, examination of the neurochemical correlates of cell death
and pharmacological approaches towards reducing excitoxicity in
these cultures was performed. Using in vivo systemic manipulations,
the dramatic dependence of QUIN on its biosynthetic precursor,
tryptophan, was determined. In turn, this observation was the basis
of an attempt to perturb physiological controls of this biosynthetic
pathway to develop a systemic model for Huntington's Disease.
However, it was shown that brain QUIN biosynthesis downregulates
in the presence of chronic elevations of its precursor. In contrast,
brain levels of the excitatory amino acid receptor antagonist,
kynurenic acid (KYA), another metabolite of tryptophan, remain
elevated, suggesting that precursor-based therapy for Huntington's
Disease might be achieved. In turn, the neuroprotective effect of
precursor therapy was demonstrated. Implications of these results
for the therapy and understanding of Huntington's Disease are
discussed.
Thesis Advisors: Professors Joseph B. Martin and Marian DiFiglia
Massachusetts General Hospital
Thesis Sponsor: Professor Gerald E. Schneider
Massachusetts Institute of Technology
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CHAPTER ONE
Introduction
Background:
In 1872, George Huntington first described a hereditary disease
entity, which now bears his name, based on clinical observations of
families in Long Island, New York (Huntington, 1872; Martin, 1984).
The victims of Huntington's Disease (HD) demonstrate a constellation
of neurologic and psychiatric symptoms and signs including
progressive motor disturbances, such as chorea, and cognitive
deterioration, ranging from subtle behavioral and mood changes to
suicidal depression and frequently progressing to severe dementia
(Martin, 1984; Bird, 1980; Bruyn, 1968; Brackenridge, 1971; Folstein,
et. al., 1983 a and b; Turner, 1985; Ford, 1986). Since Huntington's
time, enormous progress has been made in defining the pathology
and identifying the cause of this autosomal dominant disorder.
However, a precise definition of the gene defect responsible for this
disease and effective therapy for its victims are still lacking.
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Clinical Manifestations:
The disease manifests itself with a variety of initial clinical
presentations. Typically, psychiatric symptoms precede motor dis-
turbances by up to several years (Folstein, et. al., 1983 a and b).
Patients are noted frequently by their families to have subtle
behavioral changes, resulting in impulsive or erratic actions, inability
to concentrate or function at work, and the development of mood
alterations (Caine, et. al., 1978; Jason, et. al., 1988; Huber and
Paulson, 1987; Butters, et. al., 1985; Mayeux, 1984; Folstein and
Folstein, 1983). Because of these behavioral changes, patients often
become increasingly isolated from their friends and family; this
isolation compounds the patients' sense of despair. Initial motor
manifestations include subtle choreiform movements, such as 'piano-
playing' movements of the fingers (Martin, 1984).
These behavioral and motor manifestations inexorably worsen
as the disease process progresses over the following one to two
decades, until death occurs usually in the fourth or fifth decades of
life (Martin and Gusella, 1986; Myers, et. al., 1982; Bolt, 1970;
Newcombe, et al., 1981; Brackenridge, 1972). Patients develop more
pronounced choreiform movements in their extremities, rendering
these patients unable to walk and perform daily chores of living.
Normal facial motor function, swallowing, and speech become
impaired, further worsening the patients' sense of isolation and
inducing nutritional cachexia (Moldawsky, 1984; Gimenez-Roldan, et.
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al., 1971). Near the end of the disease process, the victims are often
bedbound, writhing with continuous involuntary movements and
suffering from severe malnourishment (Morales, et. al., 1989). The
typical terminal event is death due to an acute infection, such as an
aspiration pneumonia, or asphyxiation caused by choking on food
(Martin, 1984; Logemann, 1988; Lanska, et. al., 1988; Hunt and
Walker, 1989; Lanska, et. al., 1988). The emotional consequences of
the disease process are devastating as well, in large part due to the
organic dementia that is a natural correlate of the disease process,
but also because of the loneliness, isolation and depression that
results from a chronically progressive, debilitating disease (Fisher, et.
al., 1983; Brackenridge, 1980; Cummings and Benson 1984; Kurlan,
et. al., 1988; Webb and Trzepacz, 1987; Boll, et. al., 1974; Maida and
Schnaberth, 1976). Thus, it is common for a Huntington's Disease
patient to attempt suicide before he becomes physically unable to do
so (Farrer, 1986).
The effects of this disease on the victim's family are traumatic
as well (Dewhurst, et. al., 1970). Often families try to care for the
patient, but eventually find this task impossible and are forced to
seek alternative long-term care facilities. The economic and spiritual
toll that such responsibilities entail add to the burden that the
children of the patient face, already knowing that they have a 50%
chance of developing this autosomal dominant disease.
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Pathology.
The pathology of Huntington's Disease is well characterized.
There is a marked, yet selective, neuronal depletion within the
corpus striatum (Vonsattel, et. al., 1985; Bruyn, et. al., 1979). Thus,
particular striatal neuronal cell types are destroyed, while others are
spared. A preferential vulnerability of medium sized spiny
projection neurons is seen (Graveland, et. al., 1985; Pasik, et. al.,
1979). As a correlate of this cell loss, a characteristic pattern of
depletion of neurochemical markers for such cells occurs in the
striatum: levels of gamma amino butyric acid (GABA) and its
synthetic enzyme, glutamic acid decarboxylase (GAD), substance P,
dynorphin, enkephalin and calbindin are reduced (Bird, et. al., 1973;
Perry, et. al., 1973; Bird, 1980; Bird and Iversen, 1974; Spokes, 1980;
Gale, et. al., 1978; Emson, et. al., 1979 and 1980; Nemeroff, et. al.,
1983; Martin, 1984), whereas the markers of aspiny neurons,
including NADPH-diaphorase, somatostatin and neuropeptide Y, are
spared (or increased in relative concentration) (Aronin, et. al., 1983;
Dawbarn, et. al., 1985; Beal, et. al., 1988; Beal, et. al., 1986; Martin,
1984; Beal, et. al., 1984). In addition, large aspiny neurons with
markers for acetylcholinesterase and choline acetyltransferase are
relatively spared as well (Beal and Martin, 1986; Ferrante, et. al.,
1987 a and b). Finally, levels of transmitters derived from neurons
projecting to the striatum, including glutamate, dopamine, serotonin
and vasopressin are also spared in the Huntington's Disease striatum
(Martin, 1984; Beal and Martin, 1986; DiFiglia, 1990).
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Other neurochemical changes which have been observed in the
striatum include diminished levels of angiotensin converting enzyme
activity, reduced concentration and altered composition of
gangliosides, and alterations in cholecystokinin, muscarinic
cholinergic, GABA, benzodiazepine, and calcium channel antagonist
receptor populations (Hiley and Bird, 1974; Watek, et. al., 1976;
Hayes, et. al., 1981; Arregui, et. al., 1977; Arregui, et. al., 1979;
Bernheimer, et. al., 1979).
It appears that more subtle changes occur elsewhere in the
brain as well. Included among these changes are neuronal cell loss in
the cerebral cortex, the globus pallidus, the thalamus, the
subthalamic nucleus, the brainstem and portions of the substantia
nigra, although there exist conflicting reports about some of these
observations (Bruyn, et. al., 1968 and 1972; Martin, 1984; de la
Monte, et. al., 1988). Nonetheless, the earliest and most severe
damage occurs in the corpus striatum, and the degree of this damage
is closely correlated with the severity of symptoms (Myers, et. al.,
1988; VonSattel, et. al., 1985).
Genetics.
It is well established that Huntington's Disease is an autosomal
dominant disorder with a penetrance of 100% (Martin, 1984). The
origin of this gene defect (and presumed mutation) has been traced
in a number of studies to Europe, although it is now present
throughout the world (Vessie, 1932; Brothers, 1949; Bolt, 1970;
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Oliver, 1970; Scrimgeour, 1983; Lanska, et. al., 1988; Jung, et. al.,
1973; Young, et. al., 1986; Rosselli, et. al., 1987; Roccatagliata and
Albano, 1976). Until the mid 1980s, verification of Huntington's
Disease had to be performed by family history. In 1983, a restriction
fragment length polymorphism mapped to the short arm of
chromosome 4 was identified which was linked to Huntington's
Disease (Gusella, et. al., 1983). Since then, presymptomatic testing
for persons at-risk for Huntington's Disease has become available,
although many such individuals have chosen not to undergo such
testing, in part because no effective therapy is yet available (Cantor,
1984; Wexler, personal communication). The search for the identity
of the Huntington's Disease gene is ongoing but has been somewhat
hampered by the telomeric location of the disease locus on
chromosome 4 and by the evidence of different allelic genes at this
locus (Sax, et. al., 1989).
Biochemistry:
Although progress is being made towards isolating the gene
responsible for HD, the gene product and its direct
biochemical/molecular biological consequences remain a mystery.
Many studies have examined biochemical alterations in Huntington's
Disease; with a plethora of noted changes in brain, cerebrospinal fluid
(CSF), plasma, fibroblasts, erythrocytes, and other tissues. Included
among the changes observed in the CSF are altered protein gel
patterns, levels of neuropeptides, neurotransmitters, and their
metabolites, second messenger molecules, and the presence of
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cytopathic virus-like agents and additional neurotoxic agents
(Wikkelso and Blomstrand, 1982; Ulhaas, et. al., 1986; Mattsson and
Persson, 1974; Cramer, et. al., 1984; Curzon, 1975; Schwarcz, et. al.,
1988; Kurlan, et. al., 1988; Manyam, et. al., 1980; Manyam, et. al.,
1978; Enna, et. al., 1977; Glaeser, et. al., 1975; Tyrrell, et. al., 1983;
ladarola and Mouradian, 1989; Manyam, et. al., 1987; Kjellin and
Stibler, 1974; Vandvik and Skrede, 1973; Perry, et. al., 1982; Cramer,
et. al., 1981; Cunha, et. al., 1981; Caraceni, et. al., 1977; Welch, et. al.,
1976; Aquilonius, et. al., 1972; Curzon, et. al., 1972; Klawans, 1971;
Bruck, et. al., 1967; Crow, et. al., 1979; Bohlen, et. al., 1980; Glaeser,
et. al., 1975; Kremzner, et. al., 1979). Other changes include altered
growth characteristics, protein electrophoresis and glycosylation
patterns, and membrane composition of fibroblasts in culture;
changes in membrane proteins and properties in leukocytes and
erythrocytes; and disturbance of normal platelet enzyme activity
(Butterfield, et. al., 1977; Butterfield, et. al., 1978 Butterfield, et. al.,
1979; Butterfield and Markesbery, 1979 and 1981; Comings, et. al.,
1981; Fung, et. al., 1982; Pettegrew, et. al., 1979; Beverstock and
Pearson, 1981; Lakowicz and Sheppard, 1981; Dubbelman, et. al.,
1981; Goetz, et. al., 1981; Comings, 1979; Barkley, et. al., 1977; Kirk,
et. al., 1977; Leonardi, et. al., 1978; Menkes and Stein, 1973; Blough
and Baron, 1979; Appel, 1979; Tourian and Hung, 1979; Barbeau,
1979). However, these changes are likely to represent secondary
effects of this chronic disease process, rather than primary
pathogenetic alterations. In addition, some of these observations
have not been replicated.
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For a biochemical change to be relevant to the understanding of
the etiology of HD, the following criteria should apply: (i) it must be
observed in most or all patients, (ii) it must explain selective and
gradual striatal neuronal cell death, and (iii) it should be artificially
created in test animals or striatal culture preparations as a model,
and this model should show predicted effects.
Excitotoxicity:
Until the mid 1970s, none of the biochemical changes noted in
HD victims could fulfill such requirements for an effective model of
the disease process. At this time, Olney and colleagues first
demonstrated that systemic glutamate administration could cause
neurotoxicity in the arcuate nucleus of the hypothalamus,
presumably as a result of the action of glutamate in the nervous
system as an excitatory neurotransmitter (Olney and Sharpe, 1969;
Olney and Ho, 1970; Olney, et. al., 1972; Olney, et. al., 1976). Over the
subsequent years, it had become apparent that glutamate interacts
with at least three receptor sites, named for the first discovered
selective agonists of each receptor: (i) the N-methyl-D-aspartate
(NMDA) receptor, (ii) the kainic acid (KA) receptor, and (iii) the
quisqualic acid (QA) receptor (McLennan, 1983; Stone, et. al., 1981
and 1987; Foster and Fagg, 1984). The quisqualic acid (QA) receptor
has recently been renamed the Q/AMPA receptor for the greater
specificity of another agonist, amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid (AMPA, Watkins, et. al, 1990). Within the
past year, it has become further evident that there are likely to be at
20
least five glutamate receptor subtypes, the fourth being termed the
presynaptic AP4 receptor (for its selective agonist, 2-amino-4-
phosphobutyric acid) and the fifth termed the metabotropic
glutamate receptor, which stimulates the inositol phosphate/calcium
intracellular signalling pathway, shares no antagonists with other
known glutamate receptors, and has broad agonist specificity
(Watkins, 1990; Masu, et. al., 1991; Hollmann, et. al., 1991).
As a result of Olney's and other work, investigators injected
glutamate and kainic acid, a compound derived from kelp, into the
corpus striatum of rats (Coyle and Schwarcz, 1976; Schwarcz and
Coyle, 1977; McGeer and McGeer, 1976). The striatal pathology
resulting from injections of kainic acid demonstrated a selective cell
loss; large cells and axons from afferent neurons were spared.
Furthermore, neurochemical markers were depleted and behavioral
changes in test animals were reportedly similar to those seen in
Huntington's Disease patients (Schwarcz and Coyle, 1977). Glutamate
injections caused a greater degree of cell death, lacking some of the
selectivity observed with kainic acid (McGeer and McGeer, 1976). Of
interest, both kainate- and glutamate-induced neurotoxicity in the
striatum were dependent on an intact glutamatergic input from the
cortex into the striatum; ablation of this tract eliminated
excitotoxicity of exogenously administered excitotoxins (McGeer, et.
al., 1978; Schwarcz, et. al., 1984; Biziere and Coyle, 1978; Biziere and
Coyle, 1979).
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However, neither kainate nor glutamate injections provided an
ideal model. Although some of the neuropathological characteristics
of HD were seen, a number of inconsistencies appeared in subsequent
studies. Included among these inconsistencies was the observation
that neurons containing markers for somatostatin and neuropeptide
Y were not spared (Beal, et. al., 1986; Beal and Martin, 1986). Thus,
although kainic acid and glutamate provided tantalizing support that
an excitotoxic mechanism might be operative in Huntington's Disease,
these specific agents fell short of providing an exact model for the
disease.
Quinolinic Acid and Huntington's Disease:
In the early 1980s, the neuronal excitotoxic action of another
compound, quinolinic acid, was discovered (Stone and Perkins, 1981;
Schwarcz, et. al., 1983; Schwarcz, et. al., 1987). This compound was
already known to be an endogenous, intracellular metabolic
intermediate in the kynurenine pathway mediating the intracellular
conversion of tryptophan to nicotinamide adenine dinucleotide (NAD)
(Gholson, et. al., 1964). Quinolinic acid, which acts as a selective
agonist of the NMDA receptor, causes axon-sparing lesions in the
brain (Schwarcz, et. al., 1983). Injections of this compound and other
agonists of the NMDA receptor into the striatum of rats caused
neurodegeneration with marked similarities to that seen in
Huntington's Disease (Beal, et. al., 1986; Beal and Martin, 1986; Beal,
et. al., 1988). Neurons possessing particular neurochemical markers,
and striatal levels of these markers: somatostatin, neuropeptide Y,
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NADPH diaphorase, and acetyl-cholinesterase, were spared, whereas
markers for medium spiny neurons, including GABA, enkephalin,
substance P and others, were destroyed (Beal, et. al., 1986; Martin, et.
al., 1987). Other neuropathological evidence indicates the utility of
the quinolinic acid animal model of Huntington's Disease; using
receptor autoradiography, it recently has been demonstrated that the
population of neurons in the Huntington's Disease striatum containing
NMDA receptors is severely depleted (Young, et. al., 1989).
Additional evidence has pointed at the possibility that
quinolinic acid plays an etiologic role in Huntington's Disease.
Recently, the finding was made that the activity of the rate limiting
synthetic enzyme for quinolinic acid biosynthesis (Figure 1.1), 3-
Hydroxyanthranilate oxygenase (3HAO), is elevated three- to four-
fold in the Huntington's Disease post-mortem brain, whereas the
quinolinic acid degradative enzyme, quinolinate phosphoribosyl-
transferase (QPRT), is relatively unaffected (Schwarcz, et. al., 1988;
Foster and Schwarcz, 1985). Of further interest is the finding that
even in normal tissue, the maximal enzymatic rate (Vmax) for 3HAO
is approximately 80-fold higher that that for QPRT, although the
Michaelis Menten constant (Km) for both enzymes is about the same
(Freese, et. al., 1990). Thus, an increased flux of tryptophan into this
pathway could increase levels of quinolinic acid, which the
degradative enzyme of quinolinic acid, QPRT, might be unable to
remove.
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Furthermore, levels of another compound in the kynurenine
pathway, kynurenic acid, known to act as an antagonist of the NMDA
receptor, were found diminished in the CSF of Huntington's Disease
patients (Beal, et. al., 1990), suggesting that the flux of the
kynurenine pathway into quinolinic acid is augmented at the
expense of kynurenic acid production. Although studies have not
shown any elevation in quinolinic acid levels in either brain or
cerebrospinal fluid of Huntington's Disease patients (Schwarcz, et. al.,
1988; Reynolds, et. al., 1988; Heyes, et. al., 1985), these findings may
be explained by the enormous variability in quinolinic acid levels in
human brain, the short half-life of quinolinic acid in postmortem
brain, the historically poor correlation of CSF levels of compounds
with neurochemical activity in the brain, and the observation that
most Huntington's Disease post-mortem brains represent the end-
result of a chronic disease process, rather than the active disease
state itself.
If quinolinic acid, or another NMDA receptor agonist, plays a
role in the etiology of HD, a variety of observations may help explain
why neurodegeneration is relatively restricted to the corpus striatum
and why it occurs later in the patient's life. Of all the brain regions
examined in one study (Moroni, et. al., 1984 a and b), the corpus
striatum has the lowest basal levels of quinolinic acid. Perhaps this
occurs as a protective mechanism, since neurons in the striatum
show among the highest electrophysiological sensitivity to NMDA
receptor agonists of all regions in the brain (Perkins and Stone, 1983;
Stone and Burton, 1987; Koroshetz, et. al., 1990). In addition, it
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appears that the NMDA receptor in the striatum has unique
properties that distinguish it from NMDA receptors elsewhere in the
brain (Monaghan, et. al., 1988). Thus, if brain levels of quinolinic
acid are pathologically elevated, damage might occur preferentially
in the striatum. Finally, Moroni's group has shown that levels of
quinolinic acid in the brain increase as test animals age (Moroni, et.
al., 1984b), suggesting an age-dependent alteration in the
metabolism of quinolinic acid; disruption of this control might
contribute to the age-dependent onset of Huntington's Disease.
Tryptophan Metabolism and Quinolinic Acid:
The metabolism of tryptophan into quinolinic acid is complex
(Figure 1.1). Tryptophan is a precursor for a number of neuroactive
compounds, including serotonin and its metabolites; quinolinic acid;
and kynurenic acid (Fernstrom and Wurtman, 1971 a and b; Moir
and Eccleston, 1968; Freese, et. al., 1990b; Moroni, et. al., 1988 a and
b; Gal, et. al., 1978; Gal and Sherman, 1980; Gal and Sherman, 1978;
Heidelberger, et. al., 1949; Mason, 1954; Mason, 1957; Mason, 1959;
During, et. al., 1989 a and b). Regulation of the interaction among the
different branched pathways in tryptophan metabolism is poorly
understood. However, the vast majority of tryptophan is converted
peripherally into the kynurenine pathway, ultimately producing
nicotinamide adenine dinucleotide (NAD), a cofactor critical in
oxidative energy metabolism (Gholson, et. al., 1964; Heidelberger, et.
al., 1949; Swartz, et. al., 1990b; Freese, et. al., 1990b). Recent studies
have also demonstrated that the brain can convert tryptophan into
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quinolinic acid; in fact, a single intraperitoneal injection of 100 mg
tryptophan into rats caused an acute 40-fold elevation of quinolinic
acid levels in the brain (During, et. al., 1989 a and b; Freese, et. al.,
1988). Levels of serotonin under these same conditions only
increased approximately two-fold (During, et. al., 1989 a and b).
The access of tryptophan to the brain is tightly regulated by
the blood-brain barrier and other factors. Human serum albumin
binds tryptophan and thus the availability of tryptophan to cross the
blood-brain barrier is determined by the amount of free tryptophan
in plasma (Perez-Cruet, et. al., 1974; McMenamy and Oncley, 1958;
Knott and Curzon, 1972). The albumin binding is saturable; therefore
increased tryptophan levels in plasma can lead to elevated brain
levels of tryptophan. Of interest, unesterified free fatty acids can
compete with tryptophan for albumin binding sites (Curzon and
Knott, 1972). Access of tryptophan across the blood-brain barrier is
controlled by a specific large neutral amino acid transport system
that transports all large neutral amino acids, including tryptophan,
tyrosine, phenylalanine, valine, and isoleucine (Fernstrom and
Wurtman, 1971 a and b; Fernstrom and Wurtman, 1972; Pardridge,
1986). Thus, access of tryptophan to this carrier is determined by
the ratio of levels of free tryptophan to all large neutral amino acids
in plasma, rather than the level of free tryptophan in plasma alone
(Fernstrom and Wurtman, 1972; Perez-Cruet, et. al., 1974).
NA glsnewo
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Shortcomings of the Quinolinic Acid-Model:
Although a great deal of evidence supports the possibility that
an alteration in the production of quinolinic acid plays a role in the
etiology of HD, the quinolinic acid-animal model is imperfect. Some
laboratories have not found sparing of neuropeptide Y and other
neurons in quinolinic acid treated animals, although their technique
and analytical methods differed from those of Beal and others (Beal,
et. al., 1986; Boegman, et. al., 1987; Davies and Roberts, 1987; Davies
and Roberts 1988 a). In addition, the model uses very large doses
(100 mM) of quinolinic acid which are injected acutely and locally
into the corpus striatum (Beal, et. al., 1986) -- an imperfect analogy
to a chronic and presumably systemic, endogenous disorder. Recent
studies have used controlled-delivery devices containing quinolinic
acid for introducing smaller doses for extended time periods (two
months) into the striatum of rats; the HD-like neurodegeneration was
not observed in these rats (Freese, Swartz and Heyes., unpublished
observations; During, et. al., 1990; Freese, et. al., 1989a). Finally, it is
very difficult to examine mechanisms of toxicity at the cellular level
in animals; yet it is possible that a therapeutic approach to HD may
require a better understanding of the molecular mechanisms of
neurotoxicity.
It is also possible that a compound other than quinolinic acid
may activate the NMDA receptor, contributing to or inducing the
neuropathologic correlates of Huntington's Disease. An example of
such a compound is glutamate itself. Although glutamate acts at all
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three excitatory amino acid receptors, if regulation or function of the
NMDA receptor were altered by a mutation, then glutamate might
prove selectively toxic at this receptor site. We have recently shown
that in vitro NMDA receptor mediated current responses down-
regulate in the continued presence of either glutamate or N-methyl-
D-aspartate (Koroshetz, et. al., 1990; Koroshetz and Freese.
unpublished observations). If the mechanism for downregulation
were to fail or diminish, then normal glutamatergic neurotrans-
mission could prove toxic to those cells with NMDA receptors. In
addition, recent studies have shown that the NMDA receptor complex
has multiple domains, each of which is important for its normal and
controlled function (Watkins, et. al., 1990; Bettler, et. al., 1990;
Johnson and Ascher, 1987). Thus, it is also possible that Huntington's
Disease is caused by a mutation in one of the domains of the NMDA
receptor complex or the production of a compound which interacts
with or regulates one of the NMDA receptor domains, rather than by
overproduction of an excitotoxin. Finally, it has recently been shown
that it is not the absolute level of quinolinic acid which determines
neurotoxicity in the brain, but rather the ratio of quinolinic acid to
kynurenic acid, another metabolite of the kynurenine pathway which
acts as a glutamate receptor antagonist.
Objectives of these Studies:
These hypotheses and observed shortcomings of the in vivo
quinolinic-acid-animal model for Huntington's Disease have
prompted me to attempt to develop both an in vitro model for this
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disease using striatal tissue cultures, as well as a chronic, systemic
model in vivo. Advantages of tissue culture include the ability to i)
observe an isolated population of cells and follow an individual cell
over the course of time, ii) modulate and define the extracellular
environment, and iii) observe and quantify intracellular events.
Advantages of developing a systemic in vivo model include the
ability to i) more closely mimic a chronic, genetic disorder, which
presumably results in a systemic biochemical defect, ii) develop
systemic approaches to avert neuronal toxicity in the disease, and iii)
eliminate the need to use artificially high doses of toxins,
administered in a localized region of the brain.
Thus, the following (second) chapter of this thesis describes the
characterization and examination of mechanisms of excitotoxicity in
primary striatal neuronal cultures. Glutamate and selective agonists
of excitatory amino receptors were used in these studies. An
understanding of the receptor mediation and neurochemical
correlates of excitotoxin-induced neuronal cell death in these
cultures may further an understanding of the pathogenesis of
Huntington's Disease. Subsequently, the third chapter of this thesis
examines molecular modulation of excitotoxicity in striatal cultures
based on the observation that glutamate (and in particular NMDA)
receptor function can be altered by the presence of a neuronal
growth factor (Walicke, et. al., 1986; Walicke, 1988; Freese, et. al.,
1990 a and b) and that glutamate receptor activation may induce
second messenger effects, with subsequent cellular alterations.
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The fourth chapter of this thesis focuses on the attempt to
develop a systemic animal model of HD based on the observation that
peripheral precursor loading causes a dramatic increase in the levels
of quinolinic acid in the striatum (Freese, et. al., 1988; During, et. al.,
1989 a and b). The regulation of the metabolism of the kynurenine
pathway in rat brain and the production of the endogenous
antagonist to the NMDA receptor, kynurenic acid, is discussed in the
fifth chapter, with attention to possible implications for therapy in
Huntington's Disease.
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Figure 1.1
The pathway for metabolism of L-tryptophan, demonstrating the
relationship between kynurenic acid and quinolinic acid production.
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CHAPTER TWO
Characterization and Mechanism of
Excitotoxicity in Striatal Cultures
Introduction:
In vitro toxic effects of glutamate, quinolinic acid, kainic acid
and other excitotoxins have been observed in primary cultures and
brain slice preparations from several brain regions, including the
cortex, hippocampus and retina (Choi, 1987; Choi, et. al., 1987; Choi,
et. al., 1988; Rothman 1985). Until the work described in this
chapter, however, such excitotoxic effects had not been demonstrated
or characterized in the neostriatum, where glutamate is the putative
neurotransmitter of the corticostriatal pathway (Fonnum, et. al.,
1981), and thus activation of glutamate receptors may play a role in
the etiology of Huntington's Disease.
This chapter describes the characterization of the toxicity of
glutamate and selective agonists of three glutamate receptor
subtypes, NMDA, Q/AMPA, and Kainate, in primary striatal cultures
derived from neonatal rats. Despite the absence of extrinsic inputs,
cultured neonatal striatal neurons develop a variety of cell types,
synaptic connections and immunohistochemical and biochemical
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features of the in vivo neostriatum (Kessler, 1986; Messer, 1981;
Panula, 1980; Panula and Rechardt, 1979; Panula, et. al., 1979 a, b;
Pin, et. al., 1986; Simon, et. al., 1984; Skaper, et. al., 1985; Thomas,
1986; Weiss, et. al., 1986; Freese, et. al., 1990; Koroshetz, et. al., 1990)
that make them a suitable in vitro system for the study of
excitotoxin-mediated toxicity. Understanding the mechanisms and
correlates of such toxicity may lend insight into the pathogenesis of
Huntington's Disease, as well as other neurological disorders, such as
stroke, in which excitotoxins may play a role. Furthermore, effective
pharmacological approaches towards blocking excitotoxicity might be
developed from such studies.
34
Experimental Design:
Striatal cultures:
Mixed striatal cultures, with both glial and neuronal elements,
were prepared from postnatal day (PND) 0 (newborn) or PND 6 rat
pups (Sprague-Dawley, Zivic Miller, Zelienople, PA). Using sterile
technique, each pup was decapitated, and the brain was removed
and placed into a Petri dish under a dissecting microscope (American
Optical Stereo Star A0580). The anterior striatum was removed
bilaterally and placed into a Petri dish containing Tyrode's buffer
(NaCl: 140 mM, glucose: 11 mM, KCl: 4 mM, NaH2PO4: 360 pM,
KH2PO4: 180WuM, pH adjusted to 7.4 with bicarbonate) on ice. In
each dissecting session, 2-3 litters (10-15 pups/litter) were used.
After all the rat pups were sacrificed and the brains dissected, the
Tyrode's buffer was aspirated in a laminar flow hood, and
approximately 1 ml of media (50% DMEM, 50% HAMS F12, 10%
inactivated horse serum, supplemented with 100 units/ml
penicillin/streptomycin, 4 g/l glucose, Gibco, NY) was added per 10
striata. The tissue was grossly dissociated by trituration 5 times
with a 10 ml Pasteur pipette. To produce about 20 dishes/litter,
approximately 106 cells were plated into each of 35 mm dishes
(Nunclon dishes, Nunc, Denmark) pretreated for 3 hours with poly-L-
lysine (MW 75,000-150,000], Sigma Chemical, St. Louis, MO) and
subsequently washed twice with distilled water and once with
Tyrode's buffer. Culture dishes were then supplemented with 1.5 ml
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of media and placed into a 370C, 5% CO 2, humidified atmosphere in
an incubator (Forma Scientific). After 24 hours, the media in the
dishes was replenished with fresh media and after 5 days in culture
(DIC), approximately 5% of the media volume was aspirated and
replaced with media containing cytosine arabinoside (40O1M, Sigma
Chemical, St. Louis, MO), an inhibitor of mitosis, to prevent
overgrowth by glial cells. Thereafter, two-thirds of the media
volume in each dish was replaced every 3-4 days by fresh media.
Neuronal survival was not affected by the use of an alternative
medium (Eagles), in place of DMEM/HAMS F12; however all neuronal
cells died when fetal calf serum was added instead of horse serum
(results not shown).
Determination of neuronal elements in culture:
To confirm the presence of neurons in culture, Cresyl violet
staining and immunohistochemical localization of neurofilament
antigen was used. For these purposes, some of the cultures were
grown on polylysine-coated Aclar coverslips. All cultures were fixed
for 15 minutes in a 4% paraformaldehyde/phosphate-buffered saline
(PBS) solution at 370C, after which some cultures were treated with
1% Cresyl violet for 15 minutes; other cultures were incubated with
primary antibody (1:500 of mouse antineurofilament, courtesy of Dr.
C. Marotta or 1:5000 of SM33, Sternberger-Meyer) in PBS. After 48
hours, the avidin-biotin method (Vectastain, Vector Lab, Burlingame,
CA), followed by a diaminobenzidine reaction, was used for
immunohistochemical localization.
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For further confirmation of the neuronal nature of the cultured
cells, patch clamp electrophysiology was performed by Dr. Walter
Koroshetz (Koroshetz, et. al., 1990), who demonstrated voltage-
dependent ion channels on the cultured cells, and ultrastructural
examination of 12-day-old cultures showed the presence of axons
with vesicles and synaptic contacts (DiFiglia, Folsom and Freese,
unpublished results).
Assessment of toxicity:
Cultured cells, 6, 12, and 18 days in culture, were used in all
experiments. Using a marker pen, a circular coordinate system was
drawn underneath each dish which enabled relocation of selected
fields with phase contrast microscopy (32 x objective). A field with
approximately 20-30 neurons was randomly chosen from each dish
and photographed using a Zeiss inverted microscope with a modified
Polaroid camera (Newton Plastics, Newton, MA) and Polaroid 665
positive/negative film before, during, and after exposure to different
solutions. The solutions used in this study contained differing
concentrations of glutamate, CaC12, MgC12, quinolinic acid, 2-amino-5-
phosphonovalerate (APV), glycine, kynurenic acid, quisqualic acid,
and/or kainic acid. All reagents were obtained from Sigma Chemical
(St. Louis, MO), and were prepared in Tyrode's buffer (pH adjusted to
7.4 at 37oC in the presence of 5% CO2). In a typical experiment, a
field was selected and photographed, the media was aspirated from
the culture dish, 1.5 ml of the experimental solution was added, and
the dish was immediately replaced into the 370C, humidified, 5% C02
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incubator. At the designated time points, the dish was removed from
the incubator and the same field was relocated and photographed
within one minute. Control dishes were handled identically.
In preliminary studies, it was found that the use of vital dyes
to determine neuronal viability was unreliable. Therefore, a
conservative set of morphological criteria was used to assess toxicity,
before and after toxin exposure. A neuron was considered no longer
viable only if the integrity of the cell body and at least two or all
processes were destroyed (Figures 2.1 and 2.2). Because somal
swelling was found to be reversible (see results in Figure 2.4),
cavitation and shrinking of the cell body, as well as beading and/or
disappearance of processes were required as criteria for cell death.
These same criteria were applied at all culture ages throughout all
experiments.
Measurement of neuronal swelling:
Negatives were projected with a photographic enlarger and the
outlines of cell bodies were traced with a pencil. The cross-sectional
areas of the somata were measured from the drawings (Sigma Scan,
Jandel Scientific, Corte Madera, CA) and values expressed as the
mean percentage change as compared to control for each time point.
Immunocytochemistry for GABA and Enkephalin:
To determine the immunohistochemical correlates of toxicity in
striatal cultures, staining for the neurochemicals GABA and leu-
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enkephalin was performed in cultures treated with glutamate (1
mM), quinolinic acid (1 mM) or control (all for 3 hours) in the
following manner: GABA and leu-enkephalin immunohistochemistry
were performed using an Immunonuclear Rabbit primary antibody,
diluted 1:2000 in phosphate buffered saline (PBS) with 0.2% triton
and 2% goat serum. After 48 hours, the avidin-biotin method
(Vectastain, Vector Lab, Burlingame, CA), followed by a
diaminobenzidine reaction was used. Preadsorbed antibody (first
incubated overnight with 100 jig/ml antigen (GABA or leu-
enkephalin, respectively)) was used as a control, as well as dishes
incubated in the absence of primary antibody.
Data Analysis.-
The mean (+/- standard error of the mean, SEM) percentage
survival of cells for experimental values was plotted against the
concentrations of different compounds or time. Statistical
comparisons were made using ANOVA with the StatView 512
program (Brain Power, Calabasas, CA), with posthoc statistical
analysis using the Fisher PLSD.
39
Results:
General Features of the Cultures:
Primary striatal cultures derived from newborn rats contained
a variety of morphological types of neurons, similar to those
described elsewhere in detail (Kessler, 1986; Messer, 1981; Panula,
1980; Panula and Rechardt, 1979; Panula, et. al., 1979 a and b).
Immunocytochemical staining and light microscopy revealed that
46% (+/-6; mean+/-S.E.M.) of neurons had GABA-like immuno-
reactivity and 21% (+/-3) of neurons had enkephalin-like immuno-
reactivity, paralleling the in vivo striatum. (For an example of a
neuron staining for GABA-like immunoreactivity, please see Figure
2.1). Of all cells, 8% (+/-3) had large cell bodies (>10 jum diameter)
and 84% (+/-7) had intermediate cell bodies (between 5 and 10 jpm
diameter). Striatal cultures synthesized and released known striatal
neuropeptides (such as Neuropeptide Y) into the extracellular
medium (see Figure 2.2).
The cultures matured with age, and after 3-4 DIC, processes
emanated from all neurons and continued to extend and elaborate
with succeeding DIC (Figures 2.1 and 2.3). A steady drop off in cell
number occurred as the cultures aged, a feature characteristic of all
primary neuronal cultures, including striatal cultures (Kessler, 1986).
Unlike findings in other cultures derived from other brain regions,
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however, the glutamate receptor antagonist, kynurenic acid, did not
delay or attenuate this decline in cell number (results not shown).
Cells that exhibited cytoplasmic staining of Nissl substance with
the Cresyl violet stain in bright field microscopy corresponded to the
phase-positive bipolar and multipolar cells which possessed
extensive processes (compare Figure 2.3 a and b). In contrast, the
cytoplasm of the large flat cells which formed the support matrix of
the cultures failed to stain with Cresyl violet. Immunohistochemical
localization of neurofilament antigen further confirmed that the
phase-positive cells with elaborated processes were neurons (Figure
2.3 c).
Characterization of toxicity:
Neurons damaged by glutamate demonstrated initial somal
swelling within one hour after exposure and complete disruption of
neuritic processes and somal membrane integrity within 2-3 hours
(Figures 2.1, 2.4 c and d, and 2.5). Disappearance of neuritic
processes was always preceded by their swelling and blebbing,
which typically also occurred before the cell body demonstrated
membrane invaginations and further degeneration. In most cases,
after 3 hours, all that remained of a destroyed neuron was a
shrunken, irregularly shaped fraction of the cell body and occasional
particulate blebs where the processes had once existed (Figure 2.4 d).
In contrast, neurons that survived glutamate exposure demonstrated
intact cell bodies and processes (Figure 2.4b), and patch-clamp
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analysis of these cells confirmed their viability (Koroshetz, et. al.,
1990). Figure 2.5 shows the time course of neurotoxicity in 18 day
old cultures exposed to 1 mM glutamate. Using the morphological
criteria for cell death outlined in the Materials and Methods section,
significant cell loss (mean of 73% cell survival, +/-4, p < 0.001) was
observed after one hour glutamate exposure and was much greater
after three hours (mean of 54% cell survival, +/-4, p < 0.001).
Neuronal loss increased slightly with additional hours of glutamate
exposure (after 8 hours, a mean survival of 46%, +/-5 was observed),
but because of cell migration, relocating neurons after glutamate
exposure was more accurate within shorter time intervals.
Consequently, a maximum of 3 hours of excitotoxin incubation was
used for these toxicity experiments.
Somal swelling was examined in the same group of neurons
before and after exposure to 1 mM glutamate (Figure 2.6) in the
presence of low concentrations of extracellular calcium (see results
below and Figure 2.10 on the effects of calcium and glutamate
toxicity). Results showed that in 12 day old cultures, neuronal cross
sectional area increased significantly (n = 19 neurons, mean increase
of 160% of control, +/-33, p < 0.05) after one hour of glutamate
exposure and then returned to normal values after 2 hours of
glutamate treatment. These results suggest that neuronal swelling
represented a relatively early response to glutamate exposure which
could be reversed within two hours.
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Although exposure to glutamate (0.5-10 mM) produced
neuronal toxicity in striatal cultures of all ages examined (6, 12, and
18 days in culture), the degree of cell death was markedly influenced
by the age of the cultures (Figure 2.7). When exposed to 3 mM
glutamate, 6-day-old cultures showed the least toxicity (mean
neuronal survival of 91%, +/-3); striatal cells 12 days in culture
exhibited intermediate toxicity (mean neuronal survival of 76%, +/-
4); and the oldest cultures examined (18 days in culture)
demonstrated maximal toxicity with a loss of about half of the
neuronal population (mean neuronal survival of 50%, +/-5). The
ED50 for glutamate-induced neurotoxicity in the 18 day-old cultures
was approximately 300 pM. Concentrations of glutamate greater
than 3 mM did not significantly increase the loss of neurons in
cultures of any age.
To determine whether the apparent age-dependence of
susceptibility of cultured cells to glutamate was due solely to time in
culture, or could be meaningfully correlated to the ontogenetic age of
the cells, another experiment was performed. Rat pups from the
same litters were sacrificed either at PND 0 or 6, and cultures plated
identically. Subsequently, the effects of glutamate were examined in
cultures 12 days in culture (from PND 6 pups) and in cultures 12 and
18 DIC (from PND 0 pups). Results showed that upon exposure to
glutamate concentrations of 0.5-10 mM, the toxicity profile for
cultures 12 DIC derived from PND 6 rats was virtually
superimposeable upon the profile for the cultures 18 days in culture
from PND 0 rats (Figure 2.8). These results suggest that the
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summation of the age of the striatal cells, in vivo plus in vitro,
determined the age-dependence of glutamate toxicity, rather than
the age in vitro alone.
Mechanism of toxicity:
Previous studies have shown that the N-methyl-D-aspartate
(NMDA) glutamate receptor subtype activates a calcium-permeable
cation channel which can be blocked by magnesium (Nowak, et. al.,
1984). In addition, reports have indicated that activation of the
NMDA receptor is dependent on the presence of glycine in the
extracellular fluid (Johnson and Ascher, 1987; Kleckner and
Dingledine, 1988). In the presence of 1 mM glutamate, striatal
neurons 12 DIC demonstrated a toxic response to glutamate that was
affected in a dose-dependent manner by increasing concentrations of
calcium in the incubation medium (Figures 2.9 and 2.10); 82% (+/-3)
of the cells survived in the presence of 0.9 mM calcium, and only
31% (+/-2) of the neurons survived in the presence of 18 mM
calcium. In contrast, survival of cells in control cultures (without
glutamate) was unaltered by varying the extracellular calcium
concentrations between 0.45 mM and 18 mM. However, all cells
disintegrated in the complete absence of extracellular calcium,
presumably due to the loss of the glial matrix. Of interest, the
addition of glycine (1 M-1 mM) to the extracellular media had no
effect on the neurotoxic action of 1 mM glutamate on striatal neurons
12 days in culture (results not shown).
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Glutamate-mediated toxicity could be largely blocked in a
dose-dependent manner by the addition of magnesium to the
incubation media (Figure 2.11). Only 17% (+/-6) of neurons were
destroyed in the presence of the highest concentration of magnesium
tested (8 mM).
The specific NMDA agonist, quinolinic acid, was also shown to
be toxic to striatal cultures (18 days in culture), with an ED50 of
approximately 700 M (Figure 2.12). Similar to the response seen to
glutamate, neurons exposed to 1 mM quinolinic acid demonstrated a
significant cell loss within three hours (mean neuronal survival of
57%, +/-4, p< 0.001). Morphological sequelae were analagous to
those seen in the glutamate-treated cultures; those cells which were
destroyed demonstrated process degeneration and eventual somal
disruption, although antecedent somal swelling was less conspicuous.
The NMDA receptor competitive antagonist, APV, blocked
approximately one-half of glutamate-mediated toxicity in a dose-
dependent manner (Figure 2.13). Three hours following incubation
with 1 mM glutamate, only 49% (+/-3) of neurons survived in the
absence of APV, whereas in the presence of APV, 76% (+/-7) of
striatal neurons survived. Of note, the antagonist to all glutamate
receptors, kynurenic acid (0.1-10 mM), completely eliminated
glutamate toxicity (results not shown).
The incomplete blocking effect of APV on glutamate-mediated
toxicity, as well as the complete efficacy of kynurenic acid blockade,
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suggested that activation of non-NMDA receptors was also implicated
in the toxicity of glutamate in striatal cultures. After 6 days in
culture, kainic acid was toxic in a dose-dependent yet time-
independent manner (Figure 2.14). Striatal cells either 12 or 18 days
in culture showed an equal susceptibility to kainate, with a maximal
toxicity of 21 +/-6% after three hours of exposure; cells 6 days in
culture were impervious to the presence of kainic acid. In turn,
quisqualic acid (0.05-5 mM) had no toxic effect on striatal cultures
18 days in culture (results not shown).
Neurochemical correlates of excitotoxicity:
Examination of the neurochemical correlates of both glutamate
and quinolinic acid toxicity in primary striatal cultures revealed that
cells expressing certain markers (GABA and enkephalin) are
selectively lost in the quinolinic acid-treated cultures, whereas in the
presence of glutamate, all cell types appear to be affected equally
(Figures 2.1, 2.15, and 2.16). Control cultures (n=800 cells, 2
experiments) had 46% (+/-6) neurons with GABA-like
immunoreactivity and 21% (+/-3) neurons with enkephalin-like
immunoreactivity. Cultures treated with glutamate (n=600 cells, 2
experiments) had similar proportions of neurons staining for GABA-
like immunoreactivity and enkephalin-like immunoreactivity;
respectively 40% (+/-2) and 25% (+/- 2). In contrast, cultures treated
with quinolinic acid (n=600 cells, 2 experiments) had only 26% (+/-
2) neurons staining for GABA-like immunoreactivity and 13% (+/-2)%
neurons staining for enkephalin-like immunoreactivity. Thus, both
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GABA- and enkephalin-positive neurons are destroyed dispropor-
tionately by quinolinic acid; the ratios of these neurons to all neurons
in culture are not affected by glutamate. This selective cell loss
observed in the quinolinic acid treated striatal cultures parallels that
seen in test animals (rats and primates) treated with quinolinic acid
and that seen in the Huntington's Disease striatum.
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Discussion:
The application of tissue culture methods to studies on the
nervous system has a number of advantages over in vivo methods.
Included among these advantages is the ability to follow over time
either a single cell or a given population of cells under defined
extracellular conditions. This series of experiments has taken
advantage of this asset of tissue culture by characterizing neuronal
cell death induced by excitotoxins in primary striatal cultures
derived from newborn rats. The results of these studies show that
glutamate is more toxic in a dose-dependent manner to older striatal
cultures than to younger cultures. The toxicity is dependent on the
extracellular calcium concentration, can be blocked by increasing
extracellular magnesium and APV, and can be partly induced by
quinolinic acid--results consistent with a mechanism in part
dependent on the NMDA receptor. An additional component of
glutamate-mediated toxicity appeared to by mediated by non-NMDA
glutamate receptors, in particular the kainate receptor.
Similar to these findings, the concentration dependence of
glutamate toxicity has been observed in primary cultures derived
from cortex (Choi, 1987; Choi, et. al., 1987). The latter studies
showed that exposure of older cortical cultures, 15-24 days in vitro,
to 500 taM glutamate for only five minutes was sufficient to produce
widespread neuronal damage when cultures were examined 24
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hours later. These results contrast with the results reported in this
chapter, where significant cell loss was observed only after exposure
to 500 ,uM glutamate for several hours. Although the findings from
the two studies must be compared cautiously, due to differences in
methods and in the assessment of toxicity, it appears that striatal
cells in vitro are less susceptible to glutamate than cortical neurons.
This is further supported by the recent work of Koh et. al. (1989)
who reported that higher concentrations or longer exposures of
NMDA agonists were required to produce toxicity in striatal cultures
than in cortical cultures (Choi, et. al., 1987). Unlike the striatum,
where glutamate originates from extrinsic afferent inputs, the cortex
contains a large intrinsic glutamate neuronal population (Donoghue,
et. al., 1985) which may in culture favor the development of more
glutamate receptors and thus a greater susceptibility to glutamate
(Kessler, 1986). In addition, several studies have shown
concentrations of NMDA receptors to be 2-3-fold higher in cerebral
cortex than in striatum (Jarvis, et. al., 1987; Maragos, et. al., 1988;
Monaghan and Cotman, 1985). Recent studies (Monaghan, et. al.,
1988) have also suggested that the NMDA receptor in striatum is
functionally distinct from that in neocortex, the former relatively
independent of extracellular glycine concentration and the latter
dependent on glycine. The finding reported in this chapter that
NMDA-receptor-mediated toxicity in striatal cultures is independent
of exogenously added glycine is consistent with this view, as is the
preliminary finding that the in vivo toxicity of quinolinic acid in the
striatum is also not glycine sensitive (K. Swartz, personal
communication). However, since neuronal-glial cultures may release
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glycine into the extracellular media, this finding must be interpreted
with caution.
It is of interest that neurotoxic concentrations of glutamate in
vitro are significantly less than the millimolar concentrations of
glutamate found normally in the brain (Waelsch, 1951). Moreover, it
has been shown that the direct injection of at least a 50 mM
concentration of glutamate into the corpus striatum is necessary to
achieve neurotoxicity (McGeer and McGeer, 1976). It therefore
seems likely that normal protective mechanisms in the brain which
avert receptor mediated glutamate toxicity are either partially or
completely inoperative in vitro. These protective mechanisms
include the absence in vitro of a normal glutamate uptake
mechanism as observed in cortical cultures (Choi, et. al., 1987). The
observation of glutamate toxicity in striatal cultures in the absence of
glutamatergic inputs suggests that the expression of glutamate
receptors can occur independent of their afferent inputs, and raises
the question whether receptor expression may influence normal
glutamatergic synapse formation.
As shown in this study for primary striatal cultures, an age
dependence for the susceptibility to glutamate neurotoxicity has also
been observed in cortical cultures (Choi, 1987; Choi, et. al., 1987).
The greater vulnerability of older striatal cultures may be due in
part to an increase with age in the elaboration of neuritic processes
where, based on in vivo anatomical studies (Kemp and Powell, 1971),
cortical inputs, which contain glutamate (Fonnum, et. al., 1981), are
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predominantly localized. In addition, electrophysiological studies
suggest that glutamate receptors are concentrated on these processes
(Trussel, et. al., 1988). In this study, morphological observations in
vitro suggest that process degeneration precedes and may contribute
to somal destruction and neuronal loss following glutamate exposure.
Similarly, in vivo, within hours following injection of quinolinic acid
into the striatum, marked changes in dendrites and spines occur
prior to alterations in neuronal somata at the ultrastructural level
(Schwarcz, et. al., 1983; Roberts and DiFiglia, personal com-
munication). Thus, the marked abnormalities in dendrites and spines
of medium spiny neurons in Golgi impregnations of Huntington's
Disease caudate nucleus (Graveland, et. al., 1985) may be the result
of an abnormality in glutamate receptor activation.
Similar to findings in cortical and hippocampal cultures (Choi,
1987; Choi, et. al., 1987; Olney, et. al., 1986; Rothman, 1985; Rothman,
et. al., 1987; Rothman and Olney, 1987), two distinct but overlapping
phases in the neurotoxic response to glutamate are seen in striatal
cells in vitro. The first phase of response to toxic levels of glutamate
is reversible, occurs within one hour, and results in somal swelling
even in the presence of low extracellular calcium concentrations.
Somal swelling in response to glutamate exposure is thought to result
from the rapid influx of sodium and chloride ions (Choi, 1987;
Goldberg, et. al., 1986; Rothman and Olney, 1987), but the degree to
which it contributes to cell death in culture is still unclear. The other
phase of response to glutamate is marked by deterioration of neuritic
processes and delayed disintegration of the cell body and, as
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discussed below, is at least in part dependent on activation of the
NMDA receptor.
These results suggest that glutamate-induced neurotoxicity in
primary striatal cultures is in part mediated by the NMDA receptor
which permits the influx of calcium into the cell, ultimately causing
its demise (Choi, 1987; Garthwaite and Garthwaite, 1986 a and b;
Goldberg, et. al., 1986; MacDermott, et. al., 1986; Mayer and
Westbrook, 1987; Murphy, et. al., 1987). The finding that toxicity
was exacerbated by increasing extracellular calcium concentrations
and could be blocked by raising levels of magnesium in the
incubation medium are consistent with the view that toxicity is
partially mediated by the NMDA receptor. In addition, the NMDA
receptor agonist, quinolinic acid, was toxic to cultures in a dose-
dependent manner, and the specific NMDA receptor antagonist, APV,
could block much of the toxicity of glutamate in a concentration-
dependent manner. Recently, it has been shown that NMDA receptor
agonists do in fact induce intracellular accumulation of calcium in
primary murine striatal cultures (Murphy, et. al., 1987). The precise
mechanism by which intracellular accumulation of calcium can then
contribute to cell death remains poorly understood; however, it is
known that a variety of lipases, proteases and second messenger
systems are modulated by intracellular calcium levels (Garthwaite
and Garthwaite, 1986 a and b; Garthwaite, et. al., 1986; Mayer and
Westbrook, 1987; Nicoletti, et. al., 1986; Nishizuka, 1986; Rothman
and Olney, 1987; Starke, et. al., 1986; Sladeczek, et. al., 1986;
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Vaccarino, et. al., 1987; Worley, et. al., 1986). [For a further
discussion of this issue, please see Chapter 3].
Physiological studies also support the view that glutamate-
induced toxicity in striatal cultures may be partially mediated by the
NMDA receptor. Patch-clamp analysis of our striatal cultures in a
collaborative study with Dr. Walter Koroshetz (Koroshetz, et. al.,
1990) shows an age-dependent appearance in electrophysiological
responses to NMDA that in part parallels the apparent ontogeny of
glutamate susceptibility; less than one-third of cells 6-7 days in
culture had detected electrophysiological responses to 10 AuM NMDA,
whereas over two-thirds of the cells greater than 8 days in culture
had detected responses to 10 M NMDA (Figures 2.17 and 2.18).
Analogous developmental changes in glutamate receptor-mediated
electrophysiological responses have been observed in cerebellar- and
hippocampal-derived tissue preparations (Dupont, et. al., 1987;
Garthwaite, et. al., 1987; Hamon and Heinemann, 1988; Kasai, 1986).
In striatal cultures, not all cells were susceptible to either
glutamate or quinolinate induced toxicity. In fact, almost half of all
cells 18 days in culture survived short-term exposure to these
neurotoxins. Of interest, patch clamp recordings from neurons after
three hours of glutamate exposure (Koroshetz, et. al., 1990) revealed
that many still had electrophysiological responses to NMDA (Figure
2.19.). However, population histograms indicated that the surviving
neurons' electrophysiological responses to NMDA were shifted to a
lower amplitude than in control cultures (Figure 2.19).
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Immunohistochemical examination of cells surviving exposure
to glutamate, quinolinic acid, or control revealed that glutamate
exposure was equally toxic to all types of striatal neurons, including
those containing the neurochemical markers, GABA and enkephalin
(Figures 2.15 and 2.16). In contrast, quinolinic acid exposure
induced selective toxicity in certain subsets of neurons in striatal
cultures, including GABA and enkephalin, while sparing neurons with
other neurochemical markers (Figures 2.15 and 2.16). These
findings, combined with the recent report of Koh and Choi (1989)
that neurons exhibiting NADPH-diaphorase and acetylcholinesterase
are among those neurons resistant to exposure to quinolinic acid, are
strikingly similar to the neuropathological and biochemical data
obtained in the striatum of Huntington's Disease postmortem brain
and the quinolinic acid-animal model (Aronin, et. al., 1983; Ferrante,
et. al., 1985; Ferrante, et. al., 1987 a-c; McGeer and McGeer, 1976b).
These data indicate that the striatal culture system is a useful
model for understanding the neurodegeneration that occurs within
the striatum of Huntington's Disease victims. In the following
chapter, a further examination of the factors which may modulate
NMDA receptor mediated excitotoxicity in neuronal cultures is
detailed.
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Figure 2.1
Photomicrograph of a GABA-immunoreactive neuron and the age
dependent changes of striatal neurons in culture.
Photomicrograph of (a) tracings of the outlines of striatal
neurons 6, 12, and 18 days in culture demonstrating the progressive
development and maturation of neuronal processes in culture with
age; (b) a striatal GABA-immunoreactive neuron in culture,
demonstrating the extensive processes and typical morphology of
GABA-immunoreactive striatal neurons; and (c,d) a GABA-
immunoreactive neuron before and after exposure to glutamate.
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Figure 2.2
Neuropeptide Y release into culture medium.
The release of Neuropeptide Y from striatal cultures, cortical
cultures, and cortico-striatal co-cultures into the extracellular
medium compared to control medium (n=2 dishes for each data
point). Cultures 3, 6, and 9 days in culture were examined for
release of this neuropeptide into medium, demonstrating
approximately equal levels among the three different culture types.
The details of the radioimmunoassay for Neuropeptide Y are included
in the Methods Section of Chapter 4.
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Figure 2.3
Photomicrograph of striatal cultures demonstrating the appearance
and presence of neurons.
(a,b): Cresyl violet stained neurons are shown in phase contrast
(a) and bright-field (b) microscopy. Only cells exhibiting long
elaborated processes in phase optics show cytoplasmic Nissl stain in
bright field. (c): Immunohistochemical localization of neurofilament
antigen with the DAB reaction product is shown in bright field with
100 x oil objective lens. The scale bar is 50 ,gm in (a) and (b), and
20 jgm in (c).
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Figure 2.4
Toxic Effect of Glutamate on Striatal Neurons in Culture.
Striatal cells at day 6 (a,b) and day 18 (c,d) in culture before
(a,c) and after (b,d) exposure to 1 mM glutamate for 3 hours. Arrows
identify some of the cells examined before and after exposure to
glutamate. Note the marked change in the cell bodies and
disappearance of processes in the 18 day old neurons after exposure
to glutamate (compare arrows in (c) before glutamate with arrows in
(d) after glutamate); in contrast, glutamate exposure results in little
change in the 6 day old cultures (compare arrows in (a) and (b)).
Scale bar is 50 m in (a-d).
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Figure 2.5
Time course of glutamate toxicity in primary striatal cultures.
Striatal cells 18 days in culture in the presence (empty circles)
and the absence (filled squares) of 1 mM glutamate. Each value
represents the mean (+/- S.E.M.) of 12 dishes and 4 experiments.
The same dishes were examined at each time point. Incubation
media contained 1.8 mM CaC12. Beyond 0 time, each value in the
presence of glutamate is significantly different (1-way ANOVA: F 5,66
= 16.2, P = 0.0001, posthoc analysis at P < 0.05) from corresponding
values in the absence of glutamate.
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Figure 2.6
Neuronal surface area changes during glutamate exposure.
Projections of striatal neurons were traced and surface areas
measured using Sigma Scan (Jandel Scientific, Corte Madera, CA). The
surface area of 19 cells (18 DIC) was monitored before, and one hour
and two hours after exposure to 1 mM glutamate in the presence of
0.9 mM extracellular calcium. The abcissa indicates the mean
percentage (+/- S.E.M.) of 0 time surface area for each cell. Following
one hour of glutamate exposure, cell surface area was significantly
increased by 60% (P < 0.05, unpaired Student's t-test [two-tailed]).
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Figure 2.7
Concentration and age dependence of glutamate toxicity.
This figure shows the mean percentage survival (+/- S.E.M.) at
three hours of primary striatal neurons exposed to the indicated
concentrations of glutamate in the incubation media, which contained
1.8 mM CaC12 for cultures at 6 DIC (filled squares, n = 7); 12 DIC
(filled circles, n = 9); and 18 DIC (empty squares, n = 9). For
glutamate concentrations greater than 0 mM, the percentage survival
of neurons 12 DIC are significantly reduced from those for neurons 6
DIC (2-way ANOVA: F 4,30 = 5.8, P = 0.0001; posthoc statistical
analysis at P < 0.05), and for glutamate concentrations greater than
500 M, the percentage survival of neurons 18 DIC are significantly
different than those for neurons 12 DIC (P < 0.05).
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Figure 2.8
Comparison between glutamate toxicity in cultures derived from PND
O (newborn) and PND 6 rats.
Striatal cultures were incubated 12 DIC and 18 DIC in the
presence of different concentrations of glutamate and 1.8 mM CaCl 2.
Mean percentage survival (+/- S.E.M.) was monitored after three
hours for: cultures 12 DIC from PND 0 rats (filled circles, n = 9);
cultures 18 DIC from PND 0 rats (filled squares, n = 9); and cultures
12 DIC from PND 6 rats (empty circles, n = 4). The percentage
survival of cultures 12 DIC from PND 6 rats did not differ
significantly from that of cultures 18 DIC from PND 0 rats.
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Figure 2.9
Effect of extracellular calcium on glutamate induced toxicity in
striatal cultures.
Sister cultures of striatal neurons 12 DIC before (a,c) and after
(b,d) exposure to 1 mM glutamate with low extracellular calcium (0.9
mM) (a,b) and high extracellular calcium (9 mM) (c,d) in the medium.
Arrows at the same orientation in a and b and in c and d identify the
same neurons. Scale in (a-d) is 50 gim. Note the marked changes in
cell bodies and processes produced by exposing the 12 day old cells
to high calcium (compare arrows in (c) with those in (d)) whereas
glutamate has relatively little influence when low calcium is present
in the media (compare (a) with (b)).
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Figure 2.10
The calcium dependence of glutamate toxicity.
The survival of cultured striatal neurons 12 DIC was monitored
in the presence of indicated concentrations of extracellular calcium,
and in the presence (filled circles) and absence (empty squares) of 3
mM glutamate. Values represent the mean (+/- S.E.M.) of 6 dishes
and 3 experiments. In the absence of extracellular calcium, all
cellular elements (glial and neuronal) of the cultures disappeared.
All values for calcium concentrations greater than 0.9 mM are
significantly different than that for 0.9 mM calcium in the presence
of glutamate and corresponding controls (1-way ANOVA: F 6,31 =
35.99, P < 0.001; posthoc analysis P < 0.05).
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Figure 2.11
The attenuation of glutamate toxicity by extracellular magnesium.
Toxicity of primary striatal cultures (18 DIC) at three hours
was determined in the presence of 1 mM glutamate and 1.8 mM
CaCl 2 under differing extracellular magnesium concentrations.
Values represent the mean (+/- S.E.M.) of 8 dishes and 4
experiments. Asterisks indicate those points that are significantly
different from 0 mM magnesium (1-way ANOVA: F 4,39 = 8.39, P =
0.0001; posthoc analysis P < 0.05).
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Figure 2.12
Quinolinic acid toxicity dose dependence.
The survival of cultures (18 DIC) at three hours was monitored
in the presence of 1.8 mM calcium and differing concentrations of
quinolinic acid in the incubation media. Each value represents the
mean (+/- S.E.M.) of 7 dishes and 3 experiments. The percentage
survival of cultures exposed to concentrations greater than 0 mM
quinolinic acid were significantly reduced from that at 0 mM
quinolinic acid (1-way ANOVA: F3,24 = 31.38, P = 0.0001; posthoc
analysis P < 0.05).
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Figure 2.13
Blockade of glutamate toxicity by the NMDA receptor antagonist, APV.
The survival of cultured cells (18 DIC) at 3 hours was
determined in the presence of 1 mM glutamate and 1.8 mM calcium
with different doses of APV in the incubation media. Each value
represents the mean (+/- S.E.M.) of 6 dishes and 3 experiments.
Asterisks indicate those values which are significantly different from
0 mM APV (1-way ANOVA: F4,23 = 12.77, P < 0.001, posthoc analysis
P < 0.05).
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Figure 2.14
The toxicity of kainic acid in striatal cultures.
The survival of cultured striatal neurons [12 DIC (filled
squares) and 18 DIC (empty circles)] at 3 hours was determined in
the presence of differing concentrations of kainic acid and 1.8 mM
calcium. Each value represents the mean (+/- S.E.M.) of at least 4
dishes and 2 experiments. Kainic acid was not toxic to neurons 6 DIC
(results not shown).
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Figure 2.15
Quantitation of GABA-immunoreactive cells after exposure to toxins.
Comparison of the percentage of striatal cells staining for
GABA-like immunoreactivity after exposure to 3 hours of (i) control
medium, (ii) glutamate (3 mM) or (iii) quinolinate (1 mM). The bars
represent the mean (+/- SEM) of a tabulation of 1000 cells for control
and 600 cells for each of the experimental groups from 4 dishes and
2 experiments. (For quinolinic acid compared to control, p <0.05.
unpaired Student's t-test [two-tailed]; for glutamate, difference from
control not significant)
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Figure 2.16
Quantitation of Enkephalin-immunoreactive cells after exposure to
toxins.
Comparison of the percentage of striatal cells staining for
Enkephalin-like immunoreactivity after exposure to 3 hours of (i)
control medium, (ii) glutamate (3 mM) or (iii) quinolinate (1 mM).
The bars represent the mean (+/- SEM) of a tabulation of 1000 cells
for control and 600 cells for each of the experimental groups from 4
dishes and 2 experiments. (For quinolinic acid compared to control, p
<0.05, unpaired Student's t-test [two-tailed]; for glutamate, difference
from control not significant)
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Figures 2.17 and 2.18
Age-dependent changes in electrophysiological responses in striatal
cultures.
Histogram of current responses to 100 tuM NMDA in striatal
cultures 6-8 days in culture (Figure 2.17) and 8-21 days in culture
(Figure 2.18). Maximum currents induced by NMDA were obtained
in the following manner: Whole cell seals were formed and the
voltage command was -60mV. The inside solution was Cs
glucuronate; the outside solution was 0 Mg ++ Ringer's solution.
NMDA was pressure ejected from double-barreled pipettes with
separated tips (for details, please see Koroshetz, et. al., 1990). The
percentage of neurons with current responses falling within a
specific range (Y-axis) is plotted against the absolute current
amplitude (X-axis).
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Figures 2.19
Electrophysiological characteristics of striatal neurons surviving toxin
exposure.
Population histogram of NMDA responses of neurons (older
than 12 days in culture) that survived excitotoxin exposure. Cells
were exposed to 1 mM glutamate dissolved in Tyrode's buffer for 3
hours in a 5% CO 2 incubator for 3 hours at 370°C. After 3-24 hours,
the neurons were studied by the methods described in the legend to
Figures 2.17 and 2.18 and as detailed in Koroshetz, et. al., 1990. The
population histogram of the maximum 100 M NMDA (Figure 2.20)
responses from surviving neurons is plotted. For comparison to
control cultures, not exposed to excitotoxin, please see Figures 2.17
and 2.18.
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CHAPTER THREE
Molecular Modulation of NMDA
Receptor-Mediated Neurotoxicity
Introduction:
A variety of extracellular and intracellular molecules are
known to modulate glutamate (and especially NMDA) receptor
function. Each of these compounds may play an important role in
balancing normal excitatory neurotransmission with the detrimental
effects of excitotoxicity. Until recently, research on excitotoxicity in
the central nervous system has focused on the primary agonists of
glutamate receptors, including endogenously synthesized compounds
such as glutamate, aspartate, quinolinate, cysteine, as well as
exogenously derived compounds such as N-methyl-D-aspartate,
cysteine sulfinate, amino-3-hydroxy-5-methyl-4-isoxazoleproprionic
acid (AMPA), kainate and quisqualate. Now that it has become
apparent that glutamate receptors have complex, allosteric
multidomain configurations (Johnson and Ascher, 1987; Kleckner, et.
al, 1988; Watkins, et. al., 1990; Masu, et. al., 1991; Bettler, et. al.,
1990; Boulter, et. al., 1990), however, focus is turning towards
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understanding the role of additional mediators of excitatory amino
acid receptor function.
The NMDA receptor complex is believed to possess several
domains, each contributing to the receptor's physiological role in
neurotransmission (Boulter, et. al., 1990; Young, et. al., 1989;
Monaghan, et. al., 1989; Mayer and Westbrook, 1987). There is a
glycine site on the receptor complex, the activation of which has been
shown to be crucial for function in all neurons except striatal cells
(Johnson and Ascher, 1987; Kleckner, et. al., 1988; Monaghan, et. al..
1988; Freese, et. al., 1990). Kynurenic acid, a known antagonist of
the NMDA receptor, is postulated to interact with this glycine
allosteric site (Perkins and Stone, 1982; Perkins and Stone, 1985;
Ganong, et. al., 1983; Stone and Connick, 1985; Ganong and Cotman,
1986; Stone and Burton, 1987). Some evidence has suggested a link
between NMDA receptor activation and phosphatidylinositol
turnover, although it appears more likely that a distinct receptor, the
metabotropic glutamate receptor, mediates such second messenger
effects (Masu, et. al., 1991; Watkins, et. al, 1990; Sladeczek, et. al.,
1986). It is also known that the calcium channel is distinct from the
agonist binding domain (MacDermott, et. al., 1986). It is believed
that when an NMDA receptor agonist attaches to the binding domain,
a voltage dependent conformational change in the calcium channel is
induced, permitting the influx of calcium into the cell. Additional
studies suggest that there exist subtypes of NMDA receptors based
on binding site affinity differences in varying brain regions for
synthetic NMDA receptor agonists, including cis-l-aminocyclo-
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pentane- 1,3-dicarboxylic acid, piperidine dicarboxylic acid,
homoquinolinic acid, 3,4-cyclopropylglutamic acid, and trans-2-
carboxy-3-pyrrolidine acetic acid (Watkins, et. al., 1990; Olverman,
et. al., 1988; Tsai, et. al., 1988).
In addition to these identified, distinct domain sites which are
regulated by specific agonists or ligands, recent studies have
demonstrated that other compounds may play roles in modulating
glutamate (and specifically NMDA) receptor function. An example of
such a compound is the family of Fibroblast Growth Factors (FGFs),
which protect neurons against glutamate-mediated neurotoxicity
(Walicke, et. al,. 1986; Walicke and Baird, 1988; Freese, et. al., 1990;
Morrison, et. al., 1986; Unsicker, et. al., 1987). Experiments described
in this section show that the neuroprotective effect of one member of
this family of proteins, basic FGF (bFGF), may be specific to blocking
the function of the NMDA receptor complex.
Fibroblast Growth Factors: An Overview.
Fibroblast Growth Factors are a family of several related
proteins which include basic Fibroblast Growth Factor (bFGF), acidic
Fibroblast Growth Factor (aFGF), and oncogenes which share
approximately 50% sequence homology, including int-2 (associated
with breast and neck tumors), hst (associated with certain human
stomach tumors), k-FGF (associated with stomach tumors and
melanomas), and FGF-5 (associated with human bladder tumors)
(Gospodarowicz, et. al., 1987; Burgess and Maciag, 1989; Thomas,
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1987; Thomas and Gimenez-Gallego, 1986; Klagsbrun, 1991; Dickson
and Peters, 1987; Dickson, et. al., 1984; Casey, et. al., 1986; Adelaide,
et. al., 1988; Sakamoto, et. al., 1986; Taira, et. al., 1987; Yoshida, et.
al., 1987; Delli-Bovi and Basilico, 1987; Delli-Bovi, et. al., 1988; Zhan,
et. al., 1988; Marics, et. al., 1989). The term 'fibroblast growth factor'
was first coined in 1974 by Gospodarowicz, who isolated a growth
factor from pituitary gland, and since then a variety of other growth
factors, including eye derived growth factor and astroglial derived
growth factors, have been shown to be one of the known FGFs
(Gospodarowicz, 1974; Klagsbrun, 1991; Thomas, 1987; Burgess and
Maciag, 1989). FGFs have multipotential functions, including the
modulation of angiogenesis, cellular differentiation, chemotaxis,
mitogenesis, and neuronal growth and survival (Clegg, et. al., 1987;
Connolly, et. al., 1987; Presta, et. al., 1986; Sato and Rifkin, 1988;
Senior, et. al., 1986; Terranova, et. al., 1985; Gospodarowicz, et. al.,
1976; Kato and Gospodarowicz, 1985; Broad and Ham, 1983; Walicke,
et. al., 1986; Lipton, et. al., 1988; Togari, et. al., 1985; Montesano, et.
al., 1986; Gospodarowicz, et. al., 1987). Two salient features of FGFs
are: 1) their strong affinity for heparin (Shing, et. al., 1983;
Gospodarowicz, et. al., 1984; Lobb and Fett, 1984; Lobb, et. al., 1986a;
Lobb, et. al., 1986b, Maciag, et. al., 1984) and 2) their absence of a
hydrophobic signal sequence, resulting in post-transcriptional intra-
cellular localization (Abraham, et. al., 1986 a and b; Jaye, et. al., 1986;
Vlodavsky, et. al., 1987 a and b).
The two best characterized Fibroblast Growth Factors, aFGF and
bFGF, share approximately 50% sequence homology and a number of
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cellular effects, but they also differ (Esch, et. al., 1985 a and b;
Gimenez-Gallego, et. al., 1985; Gimenez-Gallego, et. al., 1986; Bohlen,
et. al., 1985). Basic FGF is a glycosylated cationic (pI 9.6) polypeptide
with a molecular weight of 18,000 kDa and a 154 amino acid
sequence (Esch, et. al., 1985b; Klagsbrun, 1991; Bohlen, et. al., 1985;
Folkman and Klagsbrun, 1987). Its gene, found on chromosome 4 in
humans, consists of three exons and two large introns, and is notable
for the absence of a signal sequence (Folkman and Klagsbrun, 1987;
Abraham, et. al., 1986). Expression of the bFGF cDNA in mammalian
cells in the absence of a signal peptide results in minimal cellular
transformation; however in the presence of a signal sequence, bFGF
becomes a potent oncogene (Kurokawa, et. al., 1987; Gospodarowicz,
et. al., 1986; Rogelij, et. al., 1988; Blam, et. al., 1988 a and b). This
observation has indicated that under normal conditions, bFGF is
sequestered within cells, bound to heparin-like molecules, including
extracellular matrix proteins with glycosaminoglycans, and denied
access to the bFGF receptor. Only in the presence of cell damage, or
in the case of the closely related FGF-like oncogenes, with transcribed
signal peptides, is the protein released extracellularly (Klagsbrun,
1990; Burgess and Maciag, 1989). Of note, bFGF is an ubiquitous
protein, found in most tissue sites, including brain and virtually all
other organs in the human body (Burgess and Maciag, 1989;
Gospodarowicz, et. al., 1987; Klagsbrun, 1990; Baird, et. al., 1986;
Sullivan and Klagsbrun, 1985; Hauschka, et. al., 1986; Brigstock, et.
al., 1989; Moscatelli, et. al., 1986; Baird, et. al., 1985 a-c; Ueno, et. al.,
1986; Hanneken, et. al., 1989; Joseph-Silverstein, et. al., 1988).
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In contrast to bFGF, aFGF is an anionic polypeptide (pI 5.6) with
a molecular weight of 18,000 kDa (Thomas, et. al., 1984). It also has
a gene composed of three exons and two introns, and lacks a signal
sequence (Jaye, et. al., 1986; Wang, et. al., 1989). There is, however,
significantly less aFGF mRNA in cells compared to bFGF mRNA (Jaye,
et. al., 1988; Blam, et. al., 1989). Acidic FGF is also more sparingly
distributed in the human body, found in particularly high
concentrations in the brain (in neurons) (Lobb and Fett, 1984;
Maciag, et. al., 1984; McKeehan and Crabb, 1987; Pettmann, et. al.,
1985).
FGF receptors have been identified on the surface of a variety
of cell types, including fibroblasts, endothelial cells and smooth
muscle cells (Neufeld and Gospodarowicz, 1985; Neufeld and
Gospodarowicz, 1986; Neufeld and Gospodarowicz, 1988; Olwin and
Hauschka, 1986; Friesel, et. al., 1986; Huang and Huang, 1986;
Moenner, et. al., 1986; Moenner, et. al., 1987). Differences in
molecular weight, affinity for the ligand, and cell surface density
have been found. Once bound to the receptor, FGFs are internalized
and degraded, resulting in the production of fragments which have
been shown to persist up to twenty-four hours (Friesel and Maciag,
1988; Bikfalvi, et. al., 1989).
The mechanism by which binding of FGFs to their receptors
transduces a signal within the cell is poorly characterized. In
contrast to the known cascade leading to tyrosine kinase activation
by such other factors as Epidermal Growth Factor binding to its
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receptor (Yarden and Ullrich, 1988), bFGF does not stimulate tyrosine
kinase activity; aFGF has been reported in some studies to stimulate
this enzyme, and in other studies to have no effect on this enzyme
(Neufeld and Gospodarowicz, 1985; Huang and Huang, 1986; Friesel,
et. al., 1989). Other established signal transduction mechanisms have
therefore been invoked for the FGF family. It has been shown that
aFGF and bFGF can stimulate formation of diacylglycerol and inositol
trisphosphate, breakdown products of phosphatidylinositol (PI)
metabolism, resulting in the stimulation of protein kinase C activity
and the intracellular mobilization of calcium, respectively (Berridge,
1987; Tsuda, et. al., 1985; Brown, et. al., 1989). Unfortunately, in
other studies, this effect has not been observed, and in fact, there is a
suggestion that FGFs may inhibit the PI-protein kinase C cascade
(Magnaldo, et. al., 1986; Mioh and Chen, 1987; Moenner, et. al., 1987;
Nanberg, et. al., 1989).
Fibroblast Growth Factors have pleiotropic cellular effects at
very low concentrations (picomolar and less). Included among these
effects are stimulation of cell proliferation; migration and
differentiation of mesodermal- and neuroectodermal-derived cells;
chemotaxis for cells, including astroglia and fibroblasts; angiogenesis
(both in development and in tumors); and neuronal differentiation,
survival and protection against excitotoxins (Connolly, et. al., 1987;
Presta, et. al., 1986; Sato and Rifkin, 1988; Senior, et. al., 1986;
Terranova, et. al., 1985; Gospodarowicz, et. al., 1976; Togari, et. al.,
1985; Walicke, et. al., 1986; Baird, et. al., 1985; Folkman and
Klagsbrun, 1987; Freese, et. al., 1991; Montesano, et. al., 1986;
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Davidson, et. al., 1985; Wagner and D'Amore, 1986; Schubert, et. al.,
1987; Lipton, et. al., 1988; Morrison, et. al., 1986; Buntrok, et. al.,
1984; Cuevas, et. al., 1988). Since the brain is the most abundant
source of FGFs, it is not surprising that they play critical roles in
normal nervous system function and development. Recent studies
have indicated that bFGF, in particular, supports the survival in
culture of neurons derived from fetal rat from a variety of brain
regions, including the hippocampus, cortex, striatum, septum and
thalamus (Walicke and Baird, 1988; Walicke, et. al., 1986; Walicke,
1988). Enhancement of survival in culture for 6 days varied by
brain region, however, and striatal neurons required the highest dose
(3 pM) and had the least neurite outgrowth response (Walicke, 1988;
Morrison, et. al., 1986). Another study has demonstrated that bFGF
can protect hippocampal neurons against glutamate-induced
excitotoxicity (100-500 pM), although the mechanism of this effect
was not investigated (Walicke, et. al., 1986).
Although the relationship between FGFs and PI hydrolysis-
protein kinase C signal transduction is poorly understood, there are
interesting suggestions that the neuroprotective effect of FGFs may
involve this signal transduction system. One of the earliest effects of
protein kinase C stimulation in neuronal-derived cell cultures is a
marked increase in membrane lipid turnover, particularly affecting
the metabolism of the predominant membrane lipid in brain,
phosphatidylcholine (Cassileth, et. al., 1981; Kinzel, et. al., 1979;
Kreibich, et. al., 1971; Liscovitch, et. al., 1985; Liscovitch, et. al., 1986;
Liscovitch, et. al., 1987). By blocking diacylglycerol (or phorbol
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ester) stimulation of protein kinase C activity, phosphatidylcholine
breakdown would be spared. When glutamate (and in particular,
NMDA) receptor agonists are applied to neuronal cultures (such as
striatal neurons) at excitotoxic doses, one of the earliest
morphological correlates of neurotoxicity is membrane disruption,
causing swelling and blebbing. Under certain conditions, these initial
effects are reversible, and the neuron can survive. Usually,
however, the membrane disruption ultimately results in cellular
demise; details of the mechanism of this cell death are unclear, as
discussed in Chapter 2. Of note, as shown in this chapter, phorbol
esters appear to protect striatal neurons against excitotoxicity, and
the initial membrane swelling and blebbing is not observed.
Whether there is a true correlation among these observed effects
remains unclear.
This chapter focuses on the characterization of the
neuroprotective effect of bFGF in striatal cultures, and then briefly
discusses the potential interaction of the PI-protein kinase C second
messenger system in mediating this neuroprotective effect.
Technical difficulties encountered in the latter experiments will also
be addressed. Finally, implications for therapy in Huntington's
Disease are reviewed.
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Experimental Design:
bFGF was kindly provided by Dr. Seth Finklestein (Harvard
Medical School); phorbol and phorbol ester (didecanoate) were
obtained from Sigma (St. Louis, MO). Cell cultures were plated and
maintained in an identical manner to that described in Chapter 2.
Neurotoxicity at two weeks in culture was monitored by tabulating
the percentage of cells which survived exposure to the excitotoxin
(dissolved in Tyrode's buffer) for the period of time indicated in the
Figure Legends in the Results Section and using identical criteria for
cell death as noted in Chapter 2.
For the studies on bFGF, striatal cultures were exposed to bFGF
(6 pM) for varying periods of time, including from the initial time of
plating (and then for two weeks), for two days before, two hours
before or at the time of exposure to the excitoxins: glutamate (3 mM),
quinolinate (1 mM), and/or kainate (1 mM) in Tyrode's buffer.
Appropriate controls included incubating cells in the absence of bFGF
and in the presence of the excitotoxin; in the absence of bFGF and in
the absence of the excitotoxin; and in the presence of bFGF and the
absence of the excitotoxin.
The studies with phorbol esters were performed in a similar
manner. Striatal neurons were maintained for two weeks in culture
and then exposed to differing concentrations of phorbol ester (TPA,
101
12-O-tetradecanoylphorbol 13-acetate: 0, 1, 10, 100, and 1000 nM,
with 0.01% Dimethylsulfoxide (DMSO)). At the same time, the
cultures were incubated in the presence or absence of 3 mM
glutamate, and the percentage of cells surviving three hours of
exposure was tabulated as shown in the Results section. An
additional control included striatal cultures incubated in the presence
of the phorbol ester parent compound, phorbol, which does not
activate protein kinase C. Furthermore, all solutions (control and
experimental) contained 0.01% DMSO, which was required to dissolve
phorbol ester in a stock solution.
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Results:
Basic Fibroblast Growth Factor Studies:
In separate experiments, striatal cultures were incubated in
the presence or absence of bFGF (6pM) from the day of plating for
12-18 days in culture. No quantifiable differences in gross
morphological characteristics of striatal neurons could be detected in
the two groups. At the time of the experiments, these cultures were
then exposed to 3 mM Glutamate, 1 mM Quinolinate, or 1 mM Kainate
for three hours, and survival of neurons was quantitated. Neurons
exposed to bFGF and subsequently glutamate had a survival (mean
+/- SEM) of 86% +/-2 (n=21 dishes, 7 experiments), whereas those
exposed to glutamate alone (without bFGF) only had a survival of
54% +/-3 (n=19 dishes, 7 experiments) (Figure 3.1). Striatal neurons
exposed to Quinolinate had a survival of 96% +/-2 (n=12 dishes, 4
experiments) in the presence of bFGF and 77% +/-4 (n=12 dishes, 4
experiments) in the absence of bFGF (Figures 3.2 and 3.3). When
exposed to Kainate, survival of neurons was not affected by
preincubation with bFGF; survival of 73% +/-7 without bFGF and
69%+/-4 with bFGF was observed (Figure 3.4). Control cultures, not
exposed to Glutamate, Quinolinate or Kainate, had a cumulative mean
survival of 99% +/-1 with and 98% +/-1 without bFGF. As seen in
Figure 3.5, the neuroprotective effect of bFGF on Glutamate-induced
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toxicity could be observed in cultures treated for as little as two
hours before toxin exposure.
Phorbol Ester Studies:
An unexpected finding was made when striatal cultures were
exposed to moderately low concentrations (as low as 100 nM) of
phorbol ester (TPA, 12-O-tetradecanoylphorbol 13-acetate). Glial
cells adjacent to neurons took on a transformed appearance within
one hour of exposure, and began a process which could be best
characterized as 'neuronophagia'. The glial cells wrapped filipod-like
processes around neurons, engulfed them shortly thereafter, and
destroyed them within a few hours (Figure 3.6). This effect was seen
in at least four separate experiments, and rendered tabulation of the
effects of phorbol ester in concentrations greater than 10 nM on
neuronal survival meaningless. Lower concentrations of phorbol
ester (10 nM or less), however, did have a significant protective
effect against glutamate induced neurotoxicity (Figure 3.7). The
inactive parent compound, phorbol, had no such effect (results not
shown).
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Discussion:
The studies reported in this chapter indicate that the
modulation of the NMDA receptor is complex. The observation that
basic fibroblast growth factor can selectively block NMDA receptor
mediated neurotoxicity in striatal neurons within as short a time
period as a few hours suggests that this protective effect is unlikely
to be due to novel protein synthesis. Puzzling aspects of these
observations also include the findings that an otherwise intracellular
protein (bFGF) can dramatically modulate cell surface glutamate
receptor function on striatal neurons and that this effect is specific
for the NMDA receptor in striatal neuronal cultures. These
observations raise the possibility that the Huntington's Disease gene
defect may result in altered function or production of bFGF or
another growth factor. This could then allow excitatory amino acid
neurotransmission to occur unabatedly, ultimately causing the
demise of certain striatal neurons via a selective NMDA receptor-
mediated mechanism. The results also suggest that striatal delivery
of bFGF [via direct injection, using delivery devices (Freese, et. al.,
1988; During, et. al., 1988), or applying genetic manipulation (Geller,
et. al., 1988; Geller et. al., 1989)], may provide a novel therapeutic
approach towards Huntington's Disease.
It remains a mystery how a growth factor might interact with
and thereby modulate the function of the NMDA receptor complex.
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This interaction may be a direct one; bFGF may bind directly to the
NMDA receptor complex or to the FGF receptors, and induce
conformational changes in the NMDA receptor complex, blocking
calcium influx into the cell. The interaction may be indirect; bFGF
may bind to its receptors, induce a second messenger cascade, and
thereby alter function of the NMDA receptor complex. Although the
second messenger systems used by FGF receptors remain poorly
characterized, some evidence has suggested that breakdown of
phosphatidylinositol (PI), with formation of diacylglycerol (DAG) and
inositol phosphates (IPs), may occur (Berridge, 1987; Tsuda, et. al.,
1985; Brown, et. al., 1989; Magnaldo, et. al., 1986; Mioh and Chen,
1987; Moenner, et. al., 1987; Nanberg, et. al., 1989; Liscovitch et. al.,
1986). These breakdown products could then activate protein kinase
C and mobilize intracellular calcium stores (Nishizuka, 1986;
Berridge, 1987), which may in turn modulate the function of the
NMDA receptor complex.
One of the earliest effects of excitoxicity in striatal cultures is
the visible swelling and blebbing of the neuronal cell membrane (see
Chapter 2). Recent evidence has also shown that one of the earliest
effects of protein kinase C activation in neural-derived cells is the
dramatic and rapid increase in cell membrane phospholipid
(particularly phosphatidylcholine) turnover (Liscovitch, et. al., 1986;
Liscovitch, et. al., 1987; Freese and Liscovitch, unpublished
observations). Although very recent studies seem to suggest that the
metabotropic glutamate receptor mediates phosphatidylinositol (PI)
turnover (Masu et. al., 1991; Watkins, et. al., 1990), some evidence
106
has indicated that the activation of other glutamate receptors in
striatal neurons may also cause breakdown of PI and initiate protein
kinase C translocation, resulting in its activation (Sladeczek, et. al.,
1986). Thus, it is conceivable that the neuroprotective effect of bFGF
is mediated via the PI/protein kinase C second messenger system.
Since investigation into this area is in its infancy, much remains to be
discovered about the mechanism of the neuroprotective effect of
growth factors. The possible relevance of such research efforts to
understanding the cause of and providing therapy for Huntington's
Disease provides additional motivation for performing further
studies on the interaction of growth factors, the function of the
NMDA receptor and the PI/protein kinase C second messenger
system.
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Figure 3.1
The effect of bFGF incubation on toxicity of glutamate in striatal
cultures.
Survival of striatal cultures treated with or without bFGF (6 pM
from the day of plating) and glutamate (GLU, 0 or 3 mM). For each
treatment condition, the values represent the mean (+/- SEM)
derived from all culture dishes (12-22 dishes per condition) obtained
from 5-7 experiments. Glutamate (0 or 3 mM) was added for 3
hours and the survival of neurons treated with bFGF and glutamate
(+FGF/+GLU) was significantly increased (one-way Anova:F3,69=86.2,
p<0.001; post hoc t-test at p<0.001) compared to those neurons not
treated with bFGF and exposed to glutamate (-FGF,+GLU). Survival
was not affected in control cultures that were not exposed to
glutamate (-FGF,-GLU; +FGF,-GLU).
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Effect of bFGF on Glutamate Toxicity
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Figure 3.2
The effect of bFGF on Quinolinic acid toxicity in striatal cultures.
Neuron survival in striatal cultures that were treated from the
day of plating with 6 pM bFGF or without bFGF and exposed to 1 mM
quinolinic acid (Quin) for 3 hours or not treated with the excitotoxin.
For each condition, values represent the mean (+/- SEM) of results of
11-12 dishes per condition from 4 experiments. Survival of neurons
treated with Quin was significantly improved by bFGF treatment
(one-way Anova F 3,43,=19.2, p<0.001; post hoc t-test at p<0.001).
Survival was unaffected in control cultures not exposed to bFGF or
Quin. Thus, the difference between survival of cells exposed to both
bFGF and Quin and survival of cells exposed to only bFGF or to
nothing at all was not statistically significant, indicating complete
protection of bFGF against Quin-induced toxicity.
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Figure 3.3
Photomicrograph demonstrating the protective effect of bFGF on
quinolinic acid-induced toxicity in striatal cultures.
Striatal cells were cultured for 14 days with (a and b) or
without bFGF (c and d): Panels a and c are two different fields that
were photographed before exposure to 1 mM Quinolinic Acid (Quin).
Panels b and d are the same fields shown in a and c, respectively,
photographed after the neurons were incubated for 3 hours with 1
mM Quin. Neurons treated with bFGF (a and b) show little change
after Quin exposure whereas those not treated with bFGF (c and d)
and exposed to Quin show a marked loss of processes and shrinkage
and vacuolization of cell bodies. Compare corresponding arrows in a
and b and in c and d. Scale bar=50 jim.
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Figure 3.4
The effect of bFGF on kainate toxicity in striatal cultures.
Neuron survival was tabulated in 12 day old striatal cultures
that were treated with or without 6 pM bFGF from the day of palting
and incubated with or without 1 mM Kainic Acid (KA) for 3 hours.
Survival of neurons exposed to both bFGF and KA (+FGF, +KA) was not
significantly improved compared to those treated with KA alone (one
way Anova F3,15=18.45, p<0.001, post hoc t-test for -FGF,+KA vs +FGF,
+KA, not significant). Survival was unaffected in control cultures not
exposed to KA and treated with or without bFGF.
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Effect of bFGF on Kainate Toxicity
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Figure 3.5
The time course of the protective effect of bFGF on Glutamate toxicity
in striatal cultures.
Striatal cultures were exposed to control or bFGF (6 pM) from
the day of plating (and subsequently for 2 weeks); or for 2 days, 2
hours, or 0 hours before the introduction of glutamate or control.
The survival of neurons after 3 hours of 3 mM glutamate or control
was then tabulated. The results shown represent the mean +/- SEM
of 10 dishes and 3 experiments. Column 1: cultures incubated with
control for 2 weeks and then exposed to glutamate; Column 2:
cultures incubated with control and then exposed to control; Column
3: cultures incubated with bFGF for 2 weeks and then exposed to
control; Column 4: cultures incubated with bFGF for 2 weeks and
then exposed to glutamate; Column 5: cultures incubated with bFGF
for 2 days and then exposed to glutamate (at 14 DIC); Column 6:
cultures incubated with bFGF for 2 hours and then exposed to
glutamate (at 14 DIC); Column 7: cultures incubated with bFGF at the
same time that glutamate was introduced (at 14 DIC). Survival of
neurons exposed to glutamate was significantly increased in all
cultures incubated with bFGF (one-way Anova:F4,39=16.7, p<0.001;
post hoc t-test at p<0.01 for Column 7 and p<0.001 for Columns 4,5,
and 6).
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Time Course of bFGF Protective Effect
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Figure 3.6
'Neuronophagia' in striatal cultures treated with 1 M phorbol ester
didecanoate (TPA).
Within one hour of exposure to TPA at concentrations greater
than 10 nM, it appeared that glial background cells took on an
altered morphology and slowly engulfed neurons and destroyed
them within three hours. There is no previous report of this
phenomenon.
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Figure 3.7
Neuroprotective effect of phorbol ester (TPA).
Striatal cultures (n=4 dishes for each group) were exposed to
10 nM TPA and 3 mM glutamate for three hours. Survival of
neurons was enhanced in the presence of TPA (p<0.05, unpaired
Student's t-test (two-tailed)
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CHAPTER FOUR
Quinolinic Acid:
In Vivo Metabolism
Introduction:
Recently, it has been shown that the activity of the rate-
limiting enzyme for quinolinic acid biosynthesis, 3-Hydroxy-
anthranilate oxygenase (3-HAO), is elevated three- to four-fold in the
Huntington's Disease brain compared to control (Schwarcz, et. al.,
1988). In contrast, the activity of the catabolic enzyme for quinolinic
acid, quinolinate phosphoribosyltransferase (QPRT), is relatively
unaltered (Foster, et. al., 1985). These observations, combined with
the finding that the Vmax of 3-HAO is 80-fold greater than that of
QPRT, provide a mechanism by which levels of quinolinic acid might
accumulate in the Huntington's Disease brain. Since quinolinic acid
levels in the striatum are normally maintained among the lowest of
all brain regions studied, and the susceptibility of neurons to NMDA-
receptor mediated toxicity is among the highest in the striatum
compared to other brain regions, elevated brain levels of quinolinic
acid might prove particularly toxic in this brain region (Moroni, et.
al., 1986 a, b; Perkins and Stone, 1983 a and b; Freese, et. al., 1990).
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A recent collaborative study among Dr. Matthew During at Yale
University School of Medicine, Dr. Melvyn Heyes at the National
Institutes of Health, Kenton Swartz at the Massachusetts General
Hospital and myself (During, et. al., 1989 a and b; Freese, et. al., 1988;
Freese, et. al., 1990) has demonstrated a marked responsiveness of
extracellular fluid quinolinic acid levels in the rat striatum to acute
parenteral tryptophan loading. As monitored by intracerebral
microdialysis, the elevations of quinolinic acid far exceeded those
seen for another neuroactive tryptophan metabolite, serotonin.
Injection of 100 or 250 mg/kg tryptophan intraperitoneally resulted
in increases of striatal extracellular fluid quinolinic acid levels of
approximately 80-fold and 230-fold (Figure 4.1), respectively, to
potentially neurotoxic levels (Whetsell, 1984), whereas extracellular
fluid levels of serotonin only increased two-fold.
This observation that brain quinolinic acid levels are markedly
precursor sensitive also has suggested a mechanism by which a
systemic model of Huntington's Disease might be generated. By
chronically loading rats with tryptophan, brain levels of quinolinic
acid could be maintained within a neurotoxic range for an extended
period of time, thereby paralleling the situation possibly occurring in
Huntington's Disease. Present animal models of Huntington's Disease
are limited by the need for acute, localized injections of high doses
(100 mM) of exogenously derived neurotoxins (Beal, et. al., 1986;
Beal, et. al., 1988). These are imperfect models of a chronic and
presumably generalized metabolic disorder which results in a
selective pathology occurring predominantly within the striatum.
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Furthermore, the generation of a chronic and systemic model for the
disease may provide better opportunities to evaluate therapeutic
approaches to Huntington's Disease on a more relevant long-term
basis.
The study described in this chapter therefore investigated the
potential neurotoxicity of chronic tryptophan loading, not only on the
striatum, but other brain regions as well. In addition, an examina-
tion was performed on the effect of chronic tryptophan loading in
rats in utero and during postnatal development on neurochemical
markers of toxicity in various brain regions, predicated on the
observation that glutamate receptor-based responses may change in
development (Koroshetz, et. al., 1990; Dupont, et. al., 1987;
Garthwaite et. al., 1987; Hamon and Heinemann, 1988).
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Experimental Design:
Feeding Studies.
Male Sprague-Dawley rats (200-300 grams) were purchased
from Charles River Laboratories (Wilmington, MA) and maintained
under standard conditions with ad libitum access to water and
Agway 3200 powdered rat chow, supplemented with L-tryptophan
(Sigma, St. Louis, MO) to a final concentration (weight/weight) of
0.3% (normal diet), 1.5%, 3.0%, and 5.0% under a twelve hour
dark/light cycle. Rats were kept on their respective diets for either
three days or two months. In the latter case, their weights were
measured each week to determine any differences among the dietary
groups; rats gained weight identically in all dietary groups, and there
was no mortality in any of the groups. At the end of each time
period (three days or two months), rats were sacrificed between 5:00
and 7:00 AM, at which time plasma levels of tryptophan were likely
to have peaked. Blood (5 ml) was collected upon decapitation,
centrifuged (Sorvall centrifuge, DuPont, Wilmington, DE) at 12,000
rpm for 10 minutes, and frozen. Brains were immediately dissected
and tissue from striatum, hippocampus, and cerebral cortex was
obtained and frozen in 0.1 N perchloric acid (Beal, et. al., 1986).
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For the studies examining the effects of tryptophan
supplementation in utero and during postnatal development,
pregnant rats (Zivic-Miller, Zelienople, PA) were obtained three days
after insemination and placed on either an 0.3% or 5.0% tryptophan
supplemented diet (Agway 3200 rat chow). At the time the rat pups
were weaned, they were then placed on either the 0.3% or 5.0%
tryptophan supplemented diet and permitted to grow to at least 200
grams, at which time they were sacrificed and their brains were
dissected and tissue sections collected as above.
Dialysis Studies:
Rats (Male Sprague-Dawley, 200-300 grams) were maintained
as above and given ad libitum access to water and Agway 3200 rat
chow (with 0.3% w/w tryptophan). Three times a day
(approximately 7 AM, 12 PM and 6 PM) an intraperitoneal injection
of tryptophan (100 mg/kg dissolved in saline) or saline control was
made; this procedure was repeated for 10 days. At the end of this
time period, microdialysis experiments were performed in the
morning as follows (During, et. al., 1987; During, et. al., 1989 a and b;
Freese, 1988): Rats were anesthetized with freshly prepared chloral
hydrate (400 mg/kg intraperitoneally), supplemented with small
additional doses throughout the experiment to maintain stable
anesthesia. Anesthetized rats were then placed in a Kopf stereotaxic
frame and dialysis probes were implanted into anterior striatum
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through small burr holes drilled into the skull at the coordinates 0.5
mm anterior to the bregma, 2.6 mm lateral to midline, and 7.0 mm
ventral to the skull surface. Dialysis probes were of concentric
construction (Sandberg design with minor modifications; During, et.
al., 1989 a and b) with a 4 mm length of exposed membrane so that
the diffusion surface spanned the dorsoventral coordinates of the rat
striatum. Hollow dialysis fibers (5 kDa cut off; Cuprophan, Hospal,
Edison, NJ) were sealed at one end with epoxy resin (Devcon,
Danvers, MA). A length of hollow vitreous silica fiber (0.17 mm
outer diameter, Anspec, MI) was inserted into the dialysis tube flush
to the sealed end. The dialysis tubing with the vitreous silica fiber
was then inserted through the length of 23 gauge stainless-steel
tubing into which another length of vitreous silica fiber had been
placed. Both ends of the 23 gauge tubing were sealed with epoxy
resin, with the dialysis membrane protruding from one end of the
probe. The length of the exposed membrane was controlled by a
coating of epoxy resin. The probe was perfused using a Carnegie
Medicin microperfusion pump (model CMA/100) via PE-50 tubing.
The perfusate consisted of an artificial extracellular fluid containing
135 mM sodium, 2.8 mM potassium, 1.0 mM magnesium, 1.2 mM
calcium, 200 M ascorbate, 2.0 mM phosphate, at pH 7.4. The flow
rate was 2.0 l/min, with fractions collected at thirty minute
intervals.
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Analytical Measurements of Quinolinic acid and Tryptophan.
Brain tissue samples were prepared and analyzed for quinolinic
acid content as previously described (Heyes and Markey, 1988) using
a highly sensitive gas chromatograph-mass spectrometry (GC-MS)
system with negative chemical ionization detection. Earlier studies
(During, et. al., 1989 a) had demonstrated that under tryptophan
loading conditions, plasma (and therefore outside the blood brain
barrier) contribution of quinolinic acid content to brain tissue content
was minimal and thus it was felt unnecessary to first flush the brains
with saline upon decapitation. Plasma tryptophan levels were
obtained using an HPLC method as previously described (During, et.
al., 1989 a and b; Anderson, et. al., 1981; Anderson, et. al., 1979).
Quantitation of Neuropeptides and GABA:
GABA was measured using a modification of the method of
Ellison, et. al. (1987). This method involves a pre-column
derivitization using 0-phthaldialdehyde/2-mercaptoethanol; followed
by high performance liquid chromatography (reverse phase) with
electrochemical detection, consisting of a Waters 712 WISP
automated sample injector, a Waters 501 Solvent delivery system, a
Bioanalytical Systems (BAS) Amperometric Electrochemical Detector
(LC-4), an Omniscribe BS 117-2 chart recorder, and a Rainin 5 ,um
Microsorb (25 cm) C-18 reverse phase column (further details in
Ellison, et. al., 1987). The BAS detector cell contained a glass carbon
working electrode and a silver/silver chloride reference electrode.
Detection of the isoindoleamine derivative was performed by
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oxidation at + 700 mV with a detector sensitivity of 10 nA/V. An
isocratic solvent system was used with a mobile phase of 0.1 M
dibasic sodium phosphate buffer and 46% (volume/volume)
methanol (HPLC solvent grade) at pH 6.0. The flow rate was kept
constant at 1.0 ml/min, resulting in an average running pressure of
2800 psi. The samples were maintained at 5C in the sample injector
during overnight automated analysis. The sensitivity of the method
for GABA quantitation was approximately 1 pmole. Tissue extracts
reconstituted in 0.1 M borate buffer (pH 9.0) were reacted with 2
mercaptoethanol/o-phthaldialdehyde reagent in the sample loop and
then automatically mixed and injected onto the column.
Neuropeptide Y, somatostatin, and substance P were measured
using well characterized radioimmunoassays (Beal and Mazurek,
1987; Arnold, et. al., 1982; Beal, et. al., 1986 b). Tissue samples were
placed into 1 ml 0.1 M HC1 and boiled for 10 minutes. These samples
were then centrifuged in a Savant eppendorf centrifuge for 10
minutes, and the supernatants lyophilized and stored at -30oC. On
the day of the assay, the lyophilates were resuspended in a neutral
buffer ('Somatostatin Buffer' as below) and assayed for substance P,
somatostatin, and/or neuropeptide Y.
Somatostatin Buffer:
This buffer consisted of the following: 0.2 M sodium phosphate
(1:1 monobasic:dibasic), 10.0 mM ethylenediamine tetraacetic acid
(EDTA, disodium salt), 50 mM sodium chloride, 0.02% sodium azide,
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0.1% bovine serum albumin, pH finally adjusted to 7.20; all reagents
were obtained from Sigma Chemical (St. Louis, MO).
Substance P Radioimmunoassav.
This assay is an equilibrium, assay which can measure
Substance-P in fmole per aliquot quantities (Beal and Mazurek,
1987). The antibody was developed in guinea pig, and thus a goat
anti-guinea pig (IgG) is used to separate bound from free Substance-
p 1251 label. The antibody (Abl) is used at a dilution of 1:2,500,000
in the assay tube (total volume of 500 l). Since the assay is run at
equilibrium conditions, Substance-P antibody and Substance-P 125
label are added simultaneously and incubated at 40C for 24 hours.
Using a sample volume of 100 pl, antibody was diluted at
1:1,500,000 in somatostatin buffer and 300 1l of this diluted
antibody was added. Then radioactive 125I labelled Substance-P was
diluted to contain 5,000 cpm/100 jil, and 100 pi of this diluted label
was added to achieve a final volume of 500 pl. Thorough vortexing
ensured proper mixing. Bound and free Substance-P label were
separated by the addition of 50 i of a 3:100 dilution of normal
guinea pig serum (NGPS) and 50 1i of a 1:10 dilution of goat anti-
guinea pig gamma globulin (GAGP IgG). These two solutions were
mixed 1:1 and 100 pl of the mixture added to the assay tubes,
making sure that precipitation was avoided by rapid addition. After
overnight incubation with NGPS and GAGP IgG at 40C, the tubes were
centrifuged for thirty minutes at 3000 rpm in a refrigerated
130
centrifuge (Sorvall). The supernatant was then aspirated and the
resulting pellet counted in a gamma counter. Reference binding
occurred typically between 45-55% of total radioactively labeled
Substance-P added. References tubes had 100 il of somatostatin
buffer in place of standard or unknown. Non-specific binding was
equal to or less than 5%. Typically, 50% displacement was achieved
with 6-7 fmol of Substance-P and the range of the standard curve
was between 1 and 20 fmol Substance-P.
Somatostatin Radioimmunoassay:
Similar to the assay for Substance-P, this assay is an
equilibrium assay designed to measure Somatostatin-14 in the
picogram per aliquot range (Arnold, et. al., 1982). The initial
antibody was developed in rabbit and goat anti-rabbit (IgG) is used
to separate bound from free Somatostatin 1251 label.
The antibody (anti-somatostatin) was diluted 1:120,000 in a
total assay volume of 600 tal. Because this is an equilibrium assay,
both Somatostatin antibody and Somatostatin 1251 label were added
simultaneously and incubated at 40C for 24 hours. With a sample
volume of 100 al, antibody was diluted 1:80,000 in somatostatin
buffer and 450 jal of the dilution added. Radioactive (125I) labeled
somatostatin was diluted to contain 10,000 cpm/100 l and 50 tl of
this label dilution was added to the incubation volume. Bound and
free somatostatin label were separated by the addition of 75 l of a
1:50 dilution of normal rabbit serum (NRS) and 75 of a 1:20
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dilution of goat anti-rabbit gamma globulin (GAR IgG). These two
solutions were mixed 1:1 and 150 ul of the mixture was added to
the incubation tubes. After overnight incubation with NRS and GAR
IgG at 40C, the tubes were centrifuged for 30 minutes at 3,000 rpm
in a refrigerated centrifuge (Sorvall). Supernatant was then
aspirated and the resulting pellet counted in a gamma counter.
Reference binding was between 40-50% of the total radioactively
labeled somatostatin added. Reference tubes had 100 tul of
somatostatin buffer in place of standard or unknown. Non-specific
binding was approximately 5 %. Non-specific binding tubes had 500
jil of somatostatin buffer and 100 u1 of somatostatin label. 50%
displacement was achieved with 25-40 pg of somatostatin and the
range of the standard curve was between 2 and 256 pg.
Neuropeptide Y Radioimmunoassay:
Again, this is an equilibrium assay designed to measure
neuropeptide Y (NPY) in picogram per aliquot quantities (Beal, et. al.,
1986 b). The antibody (Abl) is used at a final dilution of 1:50,000 in
the assay tube, with a total volume of 500 u1. Since this assay is run
at equilibrium conditions, both NPY antibody and NPY label are
added simultaneously and incubated at 4C for six days.
Assuming a sample volume of 100 ul, antibody was diluted
1:30,000 in somatostatin buffer and 300 pl of this dilution was
added to the incubation mixture. Radioactive (1251) labeled NPY was
diluted to have 5000 cpm/100 tl, and 100 pl of this diluted label
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was added to the incubation mixture. Bound and free labeled NPY
were separated by the addition of 75 ul of a 1:50 dilution of normal
rabbit serum (NRS) and 75 pi of a 1:20 dilution of goat anti-rabbit
gamma globulin (GAR IgG). These two solutions were mixed 1:1 and
150 u1l of the mixture was added to the assay tube. After overnight
incubation with NRS and GAR IgG at 40C, the tubes were centrifuged
for 30 minutes at 3000 rpm in a refrigerated centrifuge (Sorvall).
Supernatant was then aspirated and the resulting pellet counted in a
gamma counter. Reference binding was between 40-50% of the total
radioactively labeled NPY added; reference tubes had 100 ul of
somatostatin buffer in place of standard or unknown. Non-specific
binding was about 5%; non-specific binding tubes had 400 !al of
somatostatin buffer and 100 jil of labeled NPY. 50% displacement
was achieved with 40-50 pg of NPY and the range of the standard
curve was between 2 and 256 pg.
Protein Determination:
Protein determination was performed using a flourometric
method (Udenfriend, et. al., 1972) based on the use of Fluram, a
reagent which reacts with amine groups to form flourescent
combinations, allowing rapid and sensitive assay of picomolar
concentrations of proteins. The excitation and emission spectra of
the fluram derivative in acetone/borate buffer and
acetonitrile/borate buffer was established; from these emission
spectra, it is known that the maximum relative intensity of emission
is 475-490 nm, with an excitation wavelength of 390 nm. There is
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no difference in excitation and emission spectra in acetone vs.
acetonitrile. At pH 8.0, the reaction occurs with a half-life of several
milliseconds, reaching near completion within seconds. Fluram also
reacts rapidly with compounds containing hydroxyl groups, and
therefore can react through hydrolysis with the aqueous phase of the
solution. Thus, it was critical to add the Fluram reagent to the
aqueous solution while the solution was being vortexed; thus,
sufficient Fluram was brought into contact with protein before being
hydrolyzed by the aqueous phase of the solution. The details of this
reaction are, briefly: the lyophilized tissue samples were
reconstituted in 1 N NaOH, vortexed, and allowed to sit overnight.
Then aliquots were then placed into reaction test tubes (10 x 75
mm). Borate buffer (1.5 ml - x (aliquot volume) of 0.2 M Borate
buffer) was added to the aliquots and 0.5 ml of 15 mg % Fluram in
acetone was added to the vortexed samples. Then the fluorescent
emission of the reaction mixture was measured on the
spectrofluorometer, with excitation at 390 nm and emission at 480
nm. A standard curve with differing quantities of bovine serum
albumin was used to compare known protein concentrations to that
of the unknown sample.
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Results:
Effect of Tryptophan Loading on Quinolinic acid levels:
Rats fed 5% dietary tryptophan for three days were found to
have four-fold elevations of striatal and hippocampal tissue levels of
quinolinic acid over control (0.3% dietary tryptophan) (Figure 4.2).
Although these elevations in brain tissue content of quinolinic acid
are not as dramatic as seen in brain extracellular fluid as monitored
by microdialysis (Freese, 1988; During et. al., 1989 a and b), they are
consistent with the observation that acute tryptophan loading (ie.,
three days or less) has a marked effect on brain levels of quinolinic
acid. Of interest, both basal and elevated levels of quinolinic acid in
striatum are lower than in hippocampus under identical conditions,
an observation consistent with the findings of others (Moroni, et. al.,
1986 a and b).
In contrast to the acute precursor loading situation, rats fed
tryptophan (in dietary doses of 0.3, 1.5, 3.0, and 5.0%) chronically for
two months showed lesser differences in tissue quinolinic acid
content among the different dose groups. Thus, as shown in Figure
4.3, levels of quinolinic acid in striatum were essentially unaltered
by long term tryptophan feeding. Plasma levels of tryptophan,
however, remained elevated in a dose-dependent manner on
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tryptophan content in the diet (Figure 4.4). Thus, there appears to
be a down-regulation in the striatum of the responsiveness of
quinolinic acid biosynthesis to precursor loading under chronic
conditions. Of interest, striatal levels of quinolinic acid were lower
than those in cortex and hippocampus under chronic feeding
conditions as well.
To examine the possibility that quinolinic acid biosynthesis
and/or extracellular release does indeed downregulate in the
presence of chronically elevated precursor, an experiment using
intracerebral microdialysis was performed. Rats were injected three
times daily with 100 mg/kg tryptophan (n=2) or saline vehicle (n=2)
for 10 days. At the end of this time period, an acute intraperitoneal
load of tryptophan (100 mg/kg) was given, and striatal extracellular
fluid samples were collected and quantitated for quinolinic acid
levels. As shown in Figure 4.5, the rats which had received saline for
10 days demonstrated a similar amplification of quinolinic acid levels
within two hours of tryptophan administration to that seen in
previous studies (During, et. al., 1989 a and b; Freese, 1988). In
contrast, rats which had received ten prior days of intraperitoneal
injections of tryptophan demonstrated a markedly attentuated
responsiveness of extracellular fluid quinolinic acid to acute
tryptophan loading (Figure 4.5).
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Neurochemical Correlates of Toxicity.
The potential neurotoxic effects of tryptophan loading were
monitored by measurement of neuropeptide and neurotransmitter
levels in the three brain regions: corpus striatum, cortex, and
hippocampus. As markers of spiny neurons, destroyed in the
Huntington's Disease striatum and the quinolinic acid animal model
(Graveland, et. al., 1985; Aronin, et. al., 1983; Beal, et. al., 1986 a),
levels of Substance P and GABA were measured. In turn, as markers
of striatal aspiny neurons, spared in Huntington's Disease, levels of
Neuropeptide Y and somatostatin were measured (Bird and Iversen,
1974; Bird, 1980; Beal, et. al., 1989).
In the long-term tryptophan supplemented rats (1.5, 3.0, and
5.0%), levels of all peptides/transmitters were essentially unchanged
when compared to control (0.3 % dietary tryptophan) in all three
brain regions (Figures 4.6, 4.7, and 4.8) indicating the absence of any
quantifiable toxic effects of long-term tryptophan supplementation
in these brain regions. Given the observation that quinolinic acid
biosynthesis downregulates in the presence of chronically elevated
precursor levels, the absence of neurotoxicity is not surprising. Light
microscopic examination of 40 Nissl stained sections confirmed the
absence of any gross neuropathology (Dr. Neil Kowall, personal
communication, results not shown).
Reports have indicated that alterations in brain levels of
kynurenine and indoleamine metabolites occur during pre- and post-
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natal development (Moroni, et. al., 1984 a and b; Curzon and Knott,
1977; Yogman, 1986; Mathiura, et. al., 1986; Bender, 1982). In
addition, developmental changes in glutamate, and in particular
NMDA, receptor function have been noted and postulated to play a
critical role in the normal maturation of brain function (Koroshetz, et.
al., 1990; Dupont, et. al., 1987; Garthwaite, et. al., 1987; Hamon and
Heinemann, 1988). These observations suggest that the fetus or
developing animal might be more susceptible to the neurotoxic
effects of quinolinic acid and tryptophan loading. For this reason,
rats in utero were exposed to control or elevated tryptophan by
feeding their mothers rat chow supplemented with either 0.3% or
5.0% tryptophan. Tryptophan and other aromatic amino acids are
known to be transported preferentially across the placenta (Pitkin,
1984; Lenke and Levy, 1980; Levy and Waisbren, 1983), and thus
the developing fetus was exposed to tryptophan according to the
mothers' diet. Upon weaning, the pups were fed the different diets
until their sacrifice once they reached approximately 200 g. Of
interest, as shown in Figures 4.9, 4.10, 4.11, neuropeptide markers of
toxicity showed no difference between the two groups (0.3% and
5.0%) in all brain regions examined, again indicating the absence of a
neurotoxic effect of tryptophan feeding in the developing rat.
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Discussion:
The essential aromatic amino acid, tryptophan, acts not only as
a precursor for the indoleamine pathway producing serotonin, but
also for the kynurenine pathway which produces the two
neuroactive compounds, quinolinic acid and kynurenic acid (Perkins
and Stone, 1985; Stone and Connick, 1985). The former acts as an
agonist of the NMDA receptor in mammalian brain. The latter acts as
an antagonist to all subclasses of central nervous system excitatory
amino acid (glutamate) receptors, with particular efficacy at the
glycine site of the NMDA receptor (Stone and Connick, 1985; Perkins
and Stone, 1982; Ganong, et. al., 1983; Perkins and Stone, 1985; Stone
and Burton, 1987). Alterations of quinolinic acid content and thus
the ratio of quinolinic acid to kynurenic acid have been hypothesized
to be involved in the etiology of neurological diseases, including
Huntington's Disease (Foster, et. al., 1984; Freese, et. al., 1990b). Of
additional interest is the demonstration that the tryptophan
metabolite, serotonin, can modulate the sensitivity of the NMDA
receptor for its agonists, including quinolinic acid (Reynolds, et. al.,
1988).
Recently it was shown that brain extracellular fluid levels of
quinolinic acid are markedly responsive to acute tryptophan loading;
intraperitoneal injection of 100 mg/kg tryptophan elevates striatal
dialysate levels of quinolinic acid over 80-fold, within two hours
(Figure 4.1, During, et. al., 1989 a and b; Freese, 1988). In contrast, it
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has been demonstrated that striatal dialysate levels of kynurenic
acid are far less responsive to acute tryptophan loading;
intraperitoneal injection of 100 mg/kg elevates kynurenic acid levels
in striatal extracellular fluid only 8 fold, and with a lag of 6 hours
(please see Chapter V for further details; Swartz, et. al., 1990). Thus,
an acute tryptophan load will alter the ratio of brain extracellular
fluid quinolinic acid: kynurenic acid significantly, and could prove to
be neurotoxic (Freese, et. al., 1988). Based on this observation, this
series of studies was performed to examine the potential
neurotoxicity of long-term tryptophan loading using dietary
manipulations.
Several studies have already examined the potential
hepatotoxicity and carcinogenicity of tryptophan and its metabolites
(Dunning, et. al., 1950; Yoshida, et. al., 1970; Ehrhart and Stitch, 1957;
Ehrhart, et. al., 1968; Radomski, et. al., 1971; Radomski, et. al., 1977;
Matsumoto, et. al., 1976; Trulson and Sampson, 1986; Hirayama,
1971; Sidransky, et. al., 1971; Rao, et. al., 1981; Rao, et. al., 1980).
However, no other studies have examined the potential neurotoxicity
of tryptophan administration despite widespread self-administration
of large doses of tryptophan (up to several grams each day)
purchased at health-food stores until very recently. This use has
been predicated on reports of the efficacy of tryptophan in treating a
wide variety of neurological and psychiatric disorders, including
insomnia, obesity, mania, obsessive compulsive disorders, depression
and others (Schmidt, 1983; Hartmann, et. al., 1983; Spinweber, et. al.,
1983; Hartmann, 1983; Linnoila, et. al., 1980; Moldofsky and Luc,
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1989; Nicholson and Stone, 1979; Hartmann and Spinweber, 1979;
Sugden and Fletcher, 1981; Moller, et. al., 1980; Hrboticky, et. al.,
1985; Hedaya, 1984; Sved, et. al., 1982; Wilcock, et. al.; Wyatt, 1983).
Until now, the metabolic relationship of tryptophan to the
indoleamine pathway, and in particular, serotonin, has been the
suspected link for the purported efficacy of tryptophan in such
disorders (Fernstrom, et. al., 1971 a and b; Green, et. al., 1976; Moir
and Eccleston, 1968). However the recent finding that brain
extracellular fluid quinolinic acid is far more sensitive to precursor
loading suggests an alternative mechanism of action for the
purported effects of tryptophan (During, et. al., 1989 a and b; Freese,
et. al., 1990; Freese, 1988). In addition, this finding raised concern
that tryptophan self-administration was less benign than previously
suspected, given the established role of quinolinic acid as an
excitotoxin (Freese, et. al., 1988; During and Freese, 1988). Moreover,
the recently described eosinophilia myalgia syndrome has raised
additional concern about tryptophan self-administration (Flannery,
et. al., 1990; Kilbourne, et. al., 1990; Freese, et. al., 1990).
Previous studies have shown that acute injections of quinolinic
acid into the corpus striatum of rats and primates result in a pattern
of neurochemical and neuropathological changes which closely
mimics that seen in Huntington's Disease (Beal, et. al., 1986; Beal, et.
al., 1989). The activity of the direct synthetic enzyme of quinolinic
acid, 3-Hydroxyanthranilate oxygenase, is elevated 3-4 fold in post-
mortem brain of Huntington's Disease over control (Schwarcz, et. al.,
1988), and the quinolinic acid degradative enzyme, quinolinate
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phosphoribosyltransferase, is relatively unaffected (Foster, et. al.,
1985). Although several studies have demonstrated that brain tissue
quinolinic acid levels are unchanged in Huntington's Disease (Heyes,
et. al., 1985; Beal, et. al., 1990), these studies are inconclusive
because of potential post-mortem changes in quinolinic acid stability
and because they reflect the biochemistry of the terminal pathology
of Huntington's Disease, rather than the active disease process.
Furthermore, it has been demonstrated recently that cerebrospinal
fluid levels of kynurenic acid are decreased in Huntington's Disease
patients (Beal, et. al., 1990), providing a mechanism for an imbalance
in the quinolinic acid: kynurenic acid ratio. Of interest, Young's
group (1988) has recently shown that post-mortem Huntington's
Disease brains had a markedly reduced population of striatal neurons
possessing NMDA receptors, confirming that selective destruction of
neurons possessing the NMDA receptor might occur.
A number of other studies have suggested that a disorder in
tryptophan metabolism may contribute to the pathology in
Huntington's Disease. One study (Belendiuk, et. al., 1980)
demonstrated that free plasma levels of tryptophan (not bound to
albumin) were elevated in Huntington's Disease, and additional
studies (Watt and Cunningham, 1978; Perry, et. al., 1969) indicated
that the plasma levels of other large neutral amino acids were
decreased in Huntington's Disease compared to control. Since the
access of tryptophan to the large neutral amino acid carrier across
the blood-brain barrier is determined by the ratio of tryptophan to
all large neutral amino acids, both of these observations would lead
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to elevated brain tryptophan levels in Huntington's Disease.
Furthermore, one group (Belendiuk, et. al., 1980) showed a direct
correlation between free plasma tryptophan and the degree of
chorea, and another group found that daily tryptophan feeding to
juvenile Huntington's patients worsened their chorea (Barbeau,
1979), although this finding remains controversial (McLeod and
Home, 1972; Oepen and Oepen, 1969; Oliphant, et. al., 1960). Of
interest, in an animal model of glutaric aciduria, a disorder which
also causes pathological destruction of the corpus striatum and
choreoathetosis, quinolinic acid levels were found significantly
elevated (Heyes, 1987).
Based on some of these observations, this series of studies was
initiated with the hypothesis that systemic, long-term administration
of tryptophan to rats could chronically elevate brain levels of
quinolinic acid. Such an elevation might then mimic the
neurochemical and neuropathological effects of the expression of the
Huntington's Disease gene abnormality, the identity of which remains
obscure (Gusella, et. al., 1983). This approach could more closely
replicate the findings seen in Huntington's Disease and provide an
approach towards therapy, based on reducing the quinolinic acid:
kynurenic acid ratio in the brain.
However, these experiments have demonstrated the
unexpected finding that chronic administration of tryptophan does
not cause the amplification of brain quinolinic acid synthesis seen
under acute tryptophan loading conditions. The observation that the
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levels of quinolinic acid did not differ much in the brain among the
different doses of tryptophan suggests that in the presence of
chronically elevated precursors, quinolinic acid biosynthesis
downregulates. The precise mechanism of this downregulation
remains ill-defined, but may well be localized to the rate-limiting
enzyme in quinolinic acid biosynthesis, 3-hydroxyanthranilate
oxygenase. Based on the studies using intracerebral microdialysis,
this downregulation is reflected in the diminished secretion or
release of quinolinic acid into the extracellular fluid compartment in
the brain. The teleologic need over the course of evolution for down-
regulation of quinolinic acid biosynthesis within the mammalian
central nervous system remains unclear; however one might
speculate that homeostatic regulation of synthesis of a neurotoxin by
the brain is desireable, regardless of the amount of dietary intake of
amino acids.
Given the finding that quinolinic acid biosynthesis
downregulates in the presence of chronic tryptophan loading, it was
not surprising that long-term tryptophan feeding had no neurotoxic
effect in any brain region examined. Using neurochemical markers
of toxicity in the striatum, cortex, and hippocampus, as well as gross
microscopic examination, no changes occurred in any of the rats fed
either three days or two months of elevated tryptophan when
compared to control.
During development, there are alterations in the levels of
tryptophan metabolites and NMDA receptor function, suggesting that
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in utero or in early postnatal development, the rat might prove more
susceptible to any neurotoxic effects of tryptophan loading. As an
analogy, in phenylketonuria, a neurological disease involving an
alteration in the metabolism of another essential aromatic amino acid
(phenylalanine) (Levy, 1983), it is children and young adolescents
who are sensitive to dietary phenylalanine intake. Evidence also
suggests that the fetuses of mothers with this disorder may suffer
from phenylalanine toxicity in utero; concern about this has been
raised regarding the consumption of aspartame (which, when it is
metabolized, releases phenylalanine) by pregnant women. The
results in this study indicate, however, that rats exposed in utero and
during postnatal development to elevated tryptophan levels
demonstrated no evidence of quinolinic acid-mediated neurotoxicity
as monitored by neurochemical markers of toxicity in striatum,
neocortex, or hippocampus.
These findings indicate that in vivo excitotoxic lesions cannot
be produced by increasing the endogenous synthesis of quinolinic
acid via long-term tryptophan (precursor) loading, probably because
of the downregulation of quinolinic acid synthesis in the presence of
chronically elevated precursor. However, the findings do suggest
that quinolinic acid, a neurotoxin which acts at the NMDA receptor in
the brain, is regulated to avoid excessive production and release into
the extracellular space. Thus, it remains possible that a subset of the
human population, including victims of Huntington's Disease, is
susceptible to alterations in the controls of the biosynthesis of such
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compounds (Freese, et. al., 1988; Freese, et. al., 1990; Stone and
Burton. 1987; Schwarcz, et. al., 1988).
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Figure 4.1
The effect of tryptophan loading on striatal extracellular fluid levels
of quinolinic acid.
Instrastriatal monitoring of quinolinic acid levels in striatum of
rats (n=5 each group) was performed following an acute
intraperitoneal load of 0, 100 and 250 mg/kg tryptophan. There was
a marked responsiveness of extracellular fluid levels of quinolinic
acid to precursor (tryptophan) loading (for all data points greater
than 30 minutes, p<0.05 using Anova with repeated measures;
During et. al., 1989 a and b)
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Figure 4.2
Tissue levels of quinolinic acid in striatum, cortex and hippocampus
following subacute tryptophan dosing.
Rats (n= 12-15 each group) were fed differing doses of dietary
tryptophan (0.3, 1.5, 3.0, and 5.0%) for three days. As shown in this
figure, tissue quinolinic acid levels were precursor dependent in a
dose-dependent manner under the acute feeding paradigm.
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Figure 4.3
Tissue levels of quinolinic acid in striatum, cortex and hippocampus
following chronic tryptophan dosing.
Rats (n=12-15) were fed differing doses of dietary tryptophan
(0.3, 1.5, 3.0, and 5.0%) for two months. As shown in this figure,
striatal tissue quinolinic acid levels were no longer responsive to
precursor dosing under chronic feeding conditions, indicating
downregulation of quinolinic acid synthesis/release. Although there
was precursor responsiveness in cortex and hippocampus, this effect
was attenuated when compared to the acute feeding paradigm.
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Figure 4.4
Effect of chronic tryptophan loading on plasma levels of tryptophan.
Using the feeding paradigm described in Figure 4.3, plasma
levels were obtained from rats in the morning prior to their sacrifice
and analyzed for tryptophan concentration. As shown in this figure
(n=6 for each group), plasma levels of tryptophan remained directly
responsive to dietary intake under the chronic feeding paradigm.
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Figure 4.5
Downregulation of striatal extracellular fluid levels of quinolinic acid
with chronic exposure to tryptophan loading.
The apparent downregulation of quinolinic acid
biosynthesis/release into the extracellular compartment in striatum
of rats (n=2 in each group) was confirmed in the following manner.
Rats were exposed to intraperitoneal injections of tryptophan (100
mg/kg) or saline vehicle (O mg/kg tryptophan) three times a day for
10 days. At the end of this ten day period, intrastriatal microdialysis
was performed and an acute load (100 mg/kg) of tryptophan was
given intraperitoneally. Dialysates were collected and analyzed for
quinolinic acid content. As this figure shows, levels of quinolinic acid
were markedly less responsive to an acute tryptophan load in those
animals already exposed to tryptophan for ten days when compared
to control.
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Figures 4.6, 4.7, and 4.8
Effects of chronic tryptophan feedings on neurochemical markers of
toxicity in striatum, cortex and hippocampus.
Radioimmunoassays for Neuropeptide Y, Somatostatin and
Substance P, and HPLC analysis of GABA were performed on tissue
extracts of the striatum (Figure 4.6), cortex (Figure 4.7) and
hippocampus (Figure 4.8) of rats (n=20 in each group) fed a diet
containing 0.3%, 1.5%, 3.0%, and 5.0% tryptophan for two months. No
significant alteration (by Anova) in the neurochemical profiles among
the different diets in any of the brain regions examined was
observed, indicating the absence of any toxic effect of the higher
tryptophan diets.
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Figures 4.9, 4.10, and 4.11
Effects of chronic tryptophan feedings on neurochemical markers of
toxicity in striatum, cortex and hippocampus in rats exposed to
tryptophan in utero and in early development
Radioimmunoassays for Neuropeptide Y, Somatostatin and
Substance P, and HPLC analysis of GABA were performed on tissue
extracts of the striatum (Figure 4.9), cortex (Figure 4.10) and
hippocampus (Figure 4.11) of rats (n=10-12 in each group) exposed
to a diet containing 0.3%, 1.5%, 3.0%, and 5.0% tryptophan in utero
and during development for two months. No significant alteration
(by Anova) in the neurochemical profiles among the different diets
in any of the brain regions examined was observed, indicating the
absence of any toxic effect of the higher tryptophan diets during the
in utero and early developmental period.
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CHAPTER FIVE
Kynurenic Acid and
the Kynurenine Pathway
Introduction:
Perhaps the most intriguing aspect of the kynurenine pathway
in the brain is its generation of two compounds, quinolinic acid and
kynurenic acid, which have mutually antagonistic effects at the same
receptor. Quinolinic acid acts as a selective agonist of the NMDA
receptor, whereas kynurenic acid is an antagonist at all glutamate
receptors, with particular efficacy at the NMDA receptor subtype
(Perkins and Stone, 1982; Foster, et. al., 1984; Perkins and Stone,
1985; Ganong, et. al., 1983; Stone and Connick, 1985; Ganong and
Cotman, 1986; Stone and Burton, 1988). It appears that kynurenic
acid exerts this effect preferentially at the glycine allosteric site, but
acts as well at the agonist recognition site of the NMDA receptor
(Birch, et. al., 1988 a and b; Danysz, et. al., 1989).
One of the first known metabolites of tryptophan, kynurenic
acid is produced via a branch of the main pathway mediating the
conversion of tryptophan to NAD (Figure 5.1) (Heidelberger, et. al.,
1949; Homer, 1914). Presence of the enzyme, kynurenine
transaminase, which catalyzes the synthesis of kynurenic acid from
L-kynurenine, has been demonstrated in a variety of tissues,
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including liver, kidney, and brain (Mason, 1954; Mason, 1957; Mason,
1959; Mason and Gullekson, 1960; Okuno, et. al., 1980; Minatogawa,
et. al., 1974). A recent study has demonstrated the synthesis and
release of kynurenic acid in in vitro brain slice preparations in the
presence of precursor loading (Turski, et. al, 1989), and this chapter
demonstrates the physiological in vivo synthesis and release of
kynurenic acid in the rat brain.
The concomitant synthesis and extracellular release of an
agonist and antagonist of a receptor in a single biochemical pathway
suggests that the balanced production of these compounds is
important for homeostasis in the brain. Thus, the finding that levels
of CSF kynurenic acid are reduced in Huntington's Disease (Beal, et.
al., 1990) suggests that it is the ratio of quinolinic acid to kynurenic
acid, rather than absolute levels of either compound alone, which
may play an etiologic role in this disease and other neurological
disorders. In the striatal culture studies described in Chapter 2,
kynurenic acid could block entirely the toxicity of quinolinic acid.
Other studies have also demonstrated that the ratio of quinolinic acid
to kynurenic acid is critical in determining neuronal survival in vivo
and in vitro (Foster, et. al., 1984).
As described in Chapter 4 and in the results of this chapter,
quinolinic acid is far more responsive to acute tryptophan loading
than is kynurenic acid; an intraperitoneal injection into rats of 100
mg/kg of tryptophan increased striatal extracellular fluid levels of
quinolinic acid over 80-fold, whereas striatal ECF levels of kynurenic
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acid were increased less than 10-fold (see Figure 5.2). Thus, an acute
precursor loading will alter the striatal ECF ratio of quinolinic acid:
kynurenic acid in favor of neurotoxicity. However, as shown in
Chapter 4, the responsiveness of quinolinic acid to tryptophan
loading is markedly attentuated with chronic precursor loading,
indicating that downregulation of biosythesis occurs. In contrast, as
shown in the results in this chapter, kynurenic acid biosynthesis does
not downregulate in the presence of chronically elevated precursor.
Thus, a chronic tryptophan load alters the striatal ratio of quinolinic
acid: kynurenic acid in favor of neuroprotection.
The discovery that chronic administration of a biosynthetic
precursor can lower the ratio of striatal quinolinic acid: kynurenic
acid has important therapeutic implications for Huntington's Disease
and other neurological disorders. If one can manipulate the
kynurenine pathway in the striatum to alter the quinolinic acid:
kynurenic acid ratio in favor of blockade at the NMDA receptor, one
may be able to avert the neuropathological correlates of suspected
NMDA receptor-mediated toxicity in Huntington's Disease. Thus, this
chapter also examines whether chronic kynurenic acid precursor
loading offers a neuroprotective effect against quinolinic acid
injected into the corpus striatum of rats.
However, because the metabolism of tryptophan is complex,
involving several branched pathways including the indoleamine
pathway producing serotonin, long-term tryptophan administration
could prove problematic for Huntington's Disease patients. This
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concern is further supported by a number of studies indicating
peripheral toxicity of tryptophan intake in humans, and more
recently by the description of a new disease entity, eosinophilia
myalgia syndrome, in which tryptophan intake is the established
causative agent (Travis, et. al., 1990; Freese, et. al., 1990; Flannery,
et. al., 1990). Of note, levels of kynurenic acid in the striatal
extracellular fluid compartment are markedly responsive to loading
with the immediate biosynthetic precursor of kynurenic acid, 1-
kynurenine (Swartz, et. al., 1990b). In contrast, preliminary studies
indicate that brain quinolinic acid is far less responsive to systemic
kynurenine loading (Swartz, et. al., unpublished results). Thus,
whether kynurenine administration may therefore be used as
therapy for Huntington's Disease by augmenting the brain kynurenic
acid: quinolinic acid ratio is presently under consideration.
Furthermore, systemic inhibitors of kynurenine transaminase might
be developed which are precluded from passing the blood-brain
barrier. As a result, a given dose of kynurenine would have greater
impact on elevating brain kynurenic acid levels since peripheral
metabolism would be blocked. A close analogy is found in the use of
a peripheral aromatic amino acid decarboxylase inhibitor (such as
carbidopa) in conjunction with L-dopa precursor therapy to augment
brain levels of dopamine in therapy for Parkinson's Disease (Cotzias,
et. al., 1967).
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Experimental Design:
Feeding Studies:
The protocol for the feeding studies was identical to that
described in Chapter 4; however, in addition to quinolinic acid, brain
kynurenic acid levels were measured, as described below.
Furthermore, in one experiment, rats were fed tryptophan for
up to 2 months, and then injected with quinolinic acid into the left
corpus striatum to assess the neuroprotective potential of precursor
loading. In brief: rats were fed one of two doses (0.3 and 5.0%
tryptophan) for either 3 days or 2 months. At the end of each time
period (3 days or 2 months), rats (n=15 in each group) were injected
intrastriatally with 120 nmoles of quinolinic acid unilaterally (left
side) in 1 l phosphate buffered saline after anesthesia with
pentobarbitol (50 mg/kg ip). Injections were made using a 10 1
Hamilton syringe fitted with a 30 gauge blunt-tipped needle into the
left striatum at the coordinates 8.4 mm anterior to the earbar, 2.6
mm lateral to the midsaggital suture, and 4.5 mm ventral to the dura
mater. A total of 1 l was injected over a period of 2 minutes; the
needle was then left in place for an additional 2 minutes, and then
slowly withdrawn. Rats were then maintained on the respective
diets for an additional 10 days. At the end of this time period, these
rats were sacrificed, and striata, hippocampi and cortex removed
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bilaterally and stored frozen until neurochemical analysis and
radioimmunoassays could be performed. The brain sections
contralateral to the side into which quinolinic acid was injected were
used as controls.
Microdialysis Studies.
The in vivo dialysis system was essentially the same as that
described in Chapter 4. Dialysis probes were of concentric design
with 4 mm length of exposed membrane. Probes were constructed
using Sandberg's (1986) design with modifications. Hollow dialysis
fibers were sealed at one end with resin; a length of hollow vitreous
silica fiber was inserted into the dialysis tube flush to the sealed end;
and the dialysis tubing was then inserted through a length of 23
gauge stainless-steel tubing into which another length of vitreous
silica fiber (outlet) had been placed. Finally, each end of the 23
gauge tubing was sealed with resin, with the dialysis membrane
protruding from one end of the probe. The probe was perfused with
a Carnegie Medicin microperfusion pump (model CMA/100) with PE-
50 tubing using an artificial CSF, the components of which were
described in Chapter 4. Flow rates were 2.0 jil/min; fractions were
collected at 30-60 minute intervals. Probes were calibrated by
placement into standard solutions with 20 and 200 nM kynurenic
acid and subsequent measurement of the recovery of kynurenic acid
in the dialysate.
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Quantitation of neuropeptides and GABA:
The methods used for quantitation of neuropeptides
(neuropeptide Y, somatostatin, and substance P) and GABA were
detailed in the Experimental Design section of Chapter 4.
Measurement of Kynurenine Pathway metabolites:
The quantitation of quinolinic acid was performed using the
method described in Chapter 4. Kynurenic acid was quantitated
using a newly developed high performance liquid chromatography
system coupled with fluorescence detection (Swartz, et. al., 1990a).
Briefly, the system consisted of two pumps, a Waters Model 510
Solvent Delivery System and a Waters Model M45 Solvent Delivery
System; a Biorad refrigerated automatic sampler (Model AS-48), a
Waters Model 4760 Fluorescence Detector, a Shimadzu C-R5A
Chromatopac Integrator and a BBC Goerz Metrawatt SE-120 chart
recorder. The mobile phase consisted of 4.5% acetonitrile, 50 mM Na
acetate, pH adjusted to 6.2; the column was an 8 cm HR-80, C-18, 3 
reverse phase column (ESA, Bedford, MA). The flow rate was 1.0
ml/min and zinc acetate (0.5 M) was delivered post-column at the
same flow rate. Injection volumes were 50 pal; the detector had an
excitation wavelength of 344 nm and an emission wavelength of 398
nm. For measurement of kynurenic acid in dialysates, the sample
was diluted 1:1 with artificial CSF, and 50 ul injected into the HPLC
system.
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Results:
As shown in Figure 5.2 and 5.3, rats fed elevated (5%) dietary
tryptophan for 3 days had a significant increase in tissue levels of
kynurenic acid when compared to those rats fed normal (0.3%)
dietary tryptophan. The greatest effect was seen in the
hippocampus, and the least effect was in the striatum, although
increases of about 10-fold were observed in the striatum. Unlike the
case with quinolinic acid, this amplication of kynurenic acid with
tryptophan loading was not attenuated under chronic feeding
conditions. In the striatum, tissue levels of kynurenic acid remained
elevated approximately 9-fold in the presence of the 5% tryptophan
diet when compared to the normal (0.3%) tryptophan diet. The
difference between the increase in the acute (3 day) and chronic (2
month) paradigm was not significant. Thus, although the percentage
increase in striatal kynurenic acid levels following tryptophan
loading under acute conditions was less than that for quinolinic acid
(see Chapter 4), this increase in kynurenic acid production and/or
release persisted under chronic precursor loading conditions,
whereas the responsiveness of quinolinic acid to tryptophan under
chronic loading conditions dissipated in the striatum. The
mechanism of this effect is unclear, but it may be caused by
downregulation of the activity of the rate-limiting enzyme (3-
hydroxyanthranilate oxygenase) in quinolinic acid biosynthesis.
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A similar effect of tryptophan loading on kynurenic acid
biosynthesis was seen when extracellular fluid levels of kynurenic
acid were monitored in the rat striatum, as shown in Figure 5.4. This
finding not only confirms the precursor responsiveness of kynurenic
acid to tryptophan loading, but also indicates that it occurs in the
physiologically relevant extracellular fluid compartment where
kynurenic acid might have access to glutamate receptors. Of note,
the responsiveness of extracellular fluid kynurenic acid to
tryptophan loading was delayed when compared to the
responsiveness of quinolinic acid.
Finally, as shown in Figure 5.5, as monitored by neurochemical
markers of quinolinic acid induced striatal toxicity, loading rats with
a high tryptophan diet for two months provided a significant
neuroprotective effect when compared to rats fed a normal
tryptophan-containing diet. Decreases in levels of GABA and
Substance P-like immunoreactivity induced by intrastriatal 120 nmol
injections of quinolinic acid were significantly attenuated in the high
tryptophan diet.
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Discussion:
Over the past several years, evidence has suggested that it is
the ratio of agonists to antagonists available at excitatory amino acid
receptors that determine the extent of excitotoxic damage in the
brain (Foster, et. al., 1984; Stone and Connick, 1985). Predicated on
these observations, numerous antagonists to excitatory amino acid
receptors have been developed in the hope that these compounds
could prove useful in the treatment of neurodegenerative diseases
and stroke. However, all of the available synthetic antagonists have
undesireable side-effects and demonstrate other evidence of
systemic toxicity. Thus, the finding that manipulation of precursors
to kynurenic acid, the only known endogenous, direct antagonist of
excitatory amino acid receptors, can alter the level of this compound
and provide neuroprotection in the rat central nervous system may
prove important in providing a therapeutic approach to HD and other
neurological diseases. This chapter has indicated that such a
therapeutic benefit may be predicated on lowering the ratio of
quinolinic acid: kynurenic acid (or raising the kynurenic acid:
quinolinic acid ratio) in the brain.
Kynurenic acid is formed by transamination of kynurenine by
the enzyme kynurenine aminotransferase, thought to be localized in
glial cells within the CNS (Minatogawa, 1974; Turski, 1989). It is
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known that the CNS can produce kynurenine from tryptophan (Gal.
1974), but kynurenine can also be transported across the blood-
brain barrier (Gal and Sherman 1978). Kynurenine uptake systems
exist in rat brain astrocytes (Speciale, et. al., 1989) as well. Estimates
suggest that approximately 40% of brain kynurenine is endogenously
synthesized from tryptophan and the remaining 60% is transported
across the blood barrier (Swartz, et. al., 1990b). This suggests that
peripheral administration of kynurenine or tryptophan would
amplify production of kynurenic acid in brain.
The studies in this chapter have examined the responsiveness
of striatal kynurenic acid concentrations to peripheral administration
of precursors and potential in vivo neuroprotective correlates..
Intraperitoneal administration of kynurenine caused dramatic
increases in striatal ECF kynurenic acid levels (Swartz, et. al., 1990b).
Tryptophan administration also caused significant increases in
striatal tissue and ECF concentrations of kynurenic acid, albeit to a
smaller degree and at a later time interval than that seen with
kynurenince administration. This lag could be due to the peripheral
formation of kynurenine from tryptophan and the subsequent
transport of kynurenine across the blood brain barrier into glia,
where, in turn, kynurenic acid would be produced. Of note, long-
term administration of tryptophan (two months) does not result in
the downregulation of kynurenic acid production, in direct contrast
to the findings with quinolinic acid (see Chapter 4).
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Kynurenic acid is believed to act predominantly at the 'glycine
site' on the NMDA receptor. Johnson, Ascher, and colleagues (1987)
first showed that glycine can potentiate NMDA electrophysiologic
responses and proposed the existence of an allosteric modulator site
on the NMDA receptor complex sensitive to glycine (Llano, et. al.,
1988; Foster and Kemp, 1989). In fact, it appears that glycine
binding may be required for activity of the NMDA receptor (Kleckner
and Dingledine, 1988) in most areas of the brain, with one exception
being the corpus striatum (please see Chapter 2). A number of
NMDA-receptor antagonists, including kynurenic acid, appear to act
at this 'glycine site' on the NMDA-receptor complex (Foster, 1988,;
Honore, et. al., 1988; Kemp, et. al., 1988; Birch, et. al., 1989 a, b, and c;
Foster and Kemp, 1989; Lester et al, 1989; Shalaby, et. al., 1989), yet
kynurenic acid also has affinity for both the direct agonist
recognition site and the glycine responsive allosteric site on the
NDMA receptor complex. However, kynurenic acid is more potent at
the glycine allosteric site (Danysz, et. al., 1989); the EC50 of
kynurenic acid for the 'glycine site' is approximately 15 uM, whereas
the EC50 for the NMDA recognition site is approximately 200-500 uM
(Kessler, et. al., 1989; Swartz, et. al., 1990). These findings suggest
that low micromolar concentrations of kynurenic acid are required to
have activity at the glycine site on the NMDA-receptor complex.
Based on recovery estimates from intrastriatal microdialysis studies,
it is conceivable that extracellular fluid concentrations of kynurenic
acid may achieve concentrations that are neuroprotective under
precursor loading conditions.
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Evidence suggests that kynurenic acid precursor loading does
indeed provide neuroprotection against exogenously administered
quinolinic acid. As shown in Figure 5.5, neurotoxicity in the rat
striatum, as monitored by neurochemical markers of toxicity. is
significantly attenuated in rats fed a high tryptophan diet, when
compared to rats fed a normal tryptophan diet.
Further experiments are needed to better define the potential
for precursor manipulation of the kynurenine pathway and its
application to averting the neurotoxicity in Huntington's Disease. The
possibility that a simple precursor based therapy may be developed
for HD and other neurodegenerative diseases has significant
implications for patients suffering from such disease states.
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Figure 5.1
The Kynurenine Pathway
The conversion of tryptophan to kynurenine is shown. In turn.
kynurenine is converted to either kynurenic acid by kynurenine
transaminase or, after two additional intermediates, to quinolinic
acid, by the rate limiting enzyme, 3-hydroxyanthranilate oxygenase.
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Figure 5.2
Effect of acute feeding of tryptophan on brain tissue kynurenic acid
content.
Rats (n=12-15 in each group) were fed either 0.3% or 5.0%
tryptophan in their diet for 3 days. At the end of this time period,
they were sacrificed and levels of kynurenic acid (Kyn. Acid) were
measured in three brain regions: Striatum, Cortex, and Hippocampus.
As seen in this figure, in each brain region examined, there was a
significant (p<0.01, Student t-test, two tailed) increase in the tissue
level of kynurenic acid with the higher tryptophan diet.
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Figure 5.3
Effect of chronic feeding of tryptophan on brain tissue kynurenic acid
content.
Rats (n=12-15 in each group) were fed either 0.3% or 5.0%
tryptophan in their diet for 2 months. At the end of this time period,
they were sacrificed and levels of kynurenic acid (Kyn. Acid) were
measured in the striatum. As seen in this figure, there was a
significant (p<0.01, Student t-test, two tailed) increase in the tissue
level of kynurenic acid with the higher tryptophan diet. Of note, the
increase in striatal kynurenic acid in the two month-fed rats was not
significantly different than in the three day-fed rats.
182
Kynurenic Acid Levels: Chronic Feeding
1000
800 -0
* 600-
400-
ag 200-
U
Striatum
Brain Region
183
1400 -
o
.r//////
-
-
-
-
--
-
. .
I- - -
,
[20.3%
O 5. 0 O/b T
Figure 5.4
Effect of tryptophan loading on striatal extracellular fluid levels of
kynurenic acid.
Striatal extracellular fluid levels of kynurenic acid were
measured following intraperitoneal infusion (at time 0) of saline or
tryptophan (100 mg/kg). The Y axis indicates the fold-increase in
striatal kynurenic acid concentrations and the X axis indicates time in
hours. The results represent the mean (+/-SEM) of 4 (saline) or 5
(tryptophan) rats.
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Figure 5.5
The neuroprotective effect of chronic tryptophan loading.
Rats (n=12-15 in each group) were fed either 0.3% or 5.0%
tryptophan for two months. They then received an unilateral
injection of 120 nmoles of quinolinic acid, and striata were processed
for neurochemical markers of toxicity. The side contralateral to the
injection site was used as an internal control. Results indicate a
significant (p<0.05) attenuation in the decrease of GABA and
Substance P-like immunoreactivity in those rats fed the higher
tryptophan content diet, indicating a neuroprotective effect of the
higher tryptophan diet.
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Summary
The series of experiments described in this thesis has
attempted to better define potential excitotoxic mechanisms in
Huntington's Disease. Based on observations over the past fifteen
years that the neuropathology of Huntington's Disease shares many
features with experimentally induced excitotoxic damage, this thesis
has used as its hypothesis that excessive activation of an excitatory
amino acid receptor, in particular the NMDA receptor, may play a
causative role in the disease process. Because the biochemical nature
of the Huntington's gene product is not yet available, models of the
disease process are limited. However, of all the many purported
causes of this disease, the excitotoxin hypothesis is the most
attractive, in part because it closely mimics the neuropathological
effects of the disease, and because it can be experimentally induced
both in vivo and in vitro.
Using a striatal tissue culture model, examination of the
mechanism and modulation of excitotoxicity was achieved at the
cellular and molecular level. In addition, more detailed evaluation of
the pathological and neurochemical correlates of such toxicity was
performed in cultures. Studies also focused on the neuroprotective
effects of the Fibroblast Growth Factor family of proteins in striatal
cultures. This thesis then examined the manipulation of the
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kynurenine pathway in brain, which simultaneously produces an
agonist (quinolinic acid) and an antagonist (kynurenic acid) of the
NMDA receptor. Experiments examining the metabolic relationship
between these two compounds indicated that modulation of this
pathway may prove useful and feasible in providing therapy for
Huntington's Disease patients.
Many new questions have arisen as a result of these
experiments, providing the framework for future experiments. Since
rapid progress is being made towards identifying the gene product
causing Huntington's Disease, once this information is available, the
methods and approaches used in this thesis may be applied towards
providing patients therapy and towards a better understanding of
the biochemical cause of this destructive neurodegenerative disorder.
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